Clinical-grade whole genome sequencing-based haplarithmisis enables all forms of preimplantation genetic testing

Authors:
Anouk E.J. Janssen^{1,2*}, Rebekka M. Koeck^{1,2*}, Rick Essers^{1,2*}, Wanwisa van Dijk¹, Marion Drüsedau¹, Anouk E.J. Janssen^{1,2}, Rebekka M. Koeck^{1,2,} , Rick Essers^{1,2}, Wanwisa van Dijk¹, Marion Drüsedau¹
Jeroen Meekels¹, Burcu Yaldiz¹, Maartje van de Vorst¹, Ping Cao^{1,2}, Bart de Koning¹, Debby M.E.I
Hellebr , Jeroen Meekels⁺, Burcu Yaldiz⁺, Maartje van de Vorst⁺, Ping Cao^{2,2}, Bart de Koning⁺
Hellebrekers¹, Servi J.C. Stevens¹, Su Ming Sun¹, Malou Heijligers¹, Sonja A. de Munnik¹,
Uum¹, Jelle Achten¹, Lar , Chris M.J. van
T. van Golde⁵,
Ien^{1,5}, Han G.
^{1,2,7} Hellebrekers⁺, Servi J.C. Stevens⁺, Su Ming Sun⁺, Malou Heijligers⁺, Sonja A. de Munnik⁺
Uum¹, Jelle Achten¹, Lars Hamers¹, Marjan Naghdi^{1,2,3}, Lisenka E.L.M. Vissers⁴, Ron J
Guido de Wert⁶, Jos C.F.M .
T. van Golde⁵,
ien^{1,5}, Han G.
i^{1,2,7} Uum², Jelle Achten², Lars Hamers², Marjan Naghdi^{2,2,3}, Lisenka E.L.M. Vissers³
Guido de Wert⁶, Jos C.F.M. Dreesen¹, Christine de Die-Smulders^{1,2}, Edith
Brunner^{1,2,4}, Arthur van den Wijngaard¹, Aimee D.C Uum¹, Jelle Achten¹, Lars Hamers¹, Marjan Naghdi^{1,2,3}, Lisenka E.L.M. Vissers⁴, Ron J.T. van Golde⁵, , Ron J.T. van Golde³
1 Coonen^{1,5}, Han G
1i Esteki^{1,2,7} $\ddot{}$ Guido de Wert^v, Jos C.F.M. Dreesen⁺, Christine de Die-Smulders^{-he}, Edith Coonen²¹², Han G.
Brunner^{1,2,4}, Arthur van den Wijngaard¹, Aimee D.C. Paulussen^{1,2}, Masoud Zamani Esteki^{1,2,7}
*Joint first-author
Af

Affiliations:

Brunner*'**, Arthur van den Wijngaard*, Aimee D.C. Paulussen*'*, Masoud Zamani Esteki*'*'
*Joint first-author
Affiliations:
¹ Department of Clinical Genetics, Maastricht University Medical Centre (MUMC+), Maas
Netherla **Affiliations:**
¹ Department of C
Netherlands.
² Department of G t,

Department of Genetics and Cell Biology, GROW school for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands.
Department of Genetics and Cell Biology, GROW school for Oncology and Reproduction, Ma Prememant
University, Ma
Netherlands
State Controll
Maastricht, Tl 2

Department of Human Genetics and Neuroscience, Section Applied Social Psychology, Maastricht University,
Department of Human Genetics, Research Institute for Medical Innovation, Radboud University,
Department of Human Gene ³ Faculty of Psychology and Neurosciend
Maastricht, The Netherlands.
⁴ Department of Human Genetics, Rese
Medical Center, Nijmegen, The Netherlar \overline{a}

Faculty of Psychology

Maastricht, The Netherlands.

Department of Human Genetics, Research Institute for Medical Innovation, Radboud University

Medical Center, Nijmegen, The Netherlands.

Department of Obstetrics and Gyn ⁴ Department of Human Genetics, Research Institute for Medical Innovation, Radboud University

Maastricht, The Netherlands
A Department of Human Ger
Medical Center, Nijmegen, The
S Department of Obstetrics
Maastricht University, Maastri Department of Obstetrics and Gynaecology, GROW school for Oncology and Reproduction,
Department of Obstetrics and Gynaecology, GROW school for Oncology and Reproduction,
Maastricht University, Maastricht, The Netherlands.
 Ĭ,

⁵ Department of Obstetrics and Gynaeco
Maastricht University, Maastricht, The Nethe
⁶ Health, Ethics and Society, Maastricht Unicology & Developmental Biology; CAPHF Maastricht University, Maastricht, The Netherlands.

⁶ Health, Ethics and Society, Maastricht University, Maastricht, Netherlands; GROW School for

Oncology & Developmental Biology; CAPHRI School for Public Health & Prim ⁶ Health, Ethics and Society, Maastricht Universi
Oncology & Developmental Biology; CAPHRI Schoo
University, Maastricht, The Netherlands.
⁷ Division of Obstetrics and Gynaecology – Der ⁶ Health, Ethics and Society, Maastricht University, Maastricht, Netherlands; GROW School for Health, Ethics and Society, Maatsman Emersity, Maastricht, The Netherlands
Division of Obstetrics and Gynaecology – Department of Clinical Science – Intervention &
Technology (CLINTEC), Karolinska Institutet, Stockholm, Sw

Oniversity, Maastricht, The Netherlands.

⁷ Division of Obstetrics and Gynaecology – Department of Clinical Science – Intervention &

Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.

Correspondence: masou T Division of Obstetrics and Gynaecol
Technology (CLINTEC), Karolinska Institut
Correspondence: masoud.zamaniesteki@ \overline{a} Technology (CLINTEC), Karolinska Institutet, Stockholm, Sweden.
Correspondence: masoud.zamaniesteki@mumc.nl
The Mumc.nl

Technology (CLINTEC), Karolinska Institutet, Stockholm, Stockholm
Correspondence: masoud.zamaniesteki@mumc.nl Correspondence: masoud.zamaniesteki@mumc.nl

Abstract

High-throughput sequencing technologies have increasingly led to discovery of disease-causing
genetic variants, primarily in postnatal multi-cell DNA samples. However, applying these technologies
to preimplantation genetic genetic preimplantation genetic testing (PGT) in nuclear or mitochondrial DNA from single or few-cells
biopsied from *in vitro* fertilised (IVF) embryos is challenging. PGT aims to select IVF embryos without
genetic abnorm to preiming the preiming of the protopalisation genetic testing in the select of testing genetic abnormalities. Although genotyping-by-sequencing (GBS)-based haplotyping methods enabled PGT for monogenic disorders (PGT-M), Biopsied from in the fertilies (IV) embryosite challenging. Per aims to select IVF embry of minicity
genetic abnormalities. Although genotyping-by-sequencing (GBS)-based haplotyping methods
enabled PGT for monogenic disord enabled PGT for monogenic disorders (PGT-M), structural rearrangements (PGT-SR), and aneuploidies
(PGT-A), they are labour intensive, only partially cover the genome and are troublesome for difficult
loci and consanguineou enabled PGT-A), they are labour intensive, only partially cover the genome and are troublesome for difficult
loci and consanguineous couples. Here, we devised a simple, scalable and universal whole genome
sequencing haplar (PGT-A), the set of the general order and universal whole genome
sequencing haplarithmisis-based approach enabling all forms of PGT in a single assay. In a comparison
to state-of-the-art GBS-based PGT for nuclear DNA (37 e depending haplarithmisis-based approach enabling all forms of PGT in a single assay. In a comparison
to state-of-the-art GBS-based PGT for nuclear DNA (37 embryos, 18 families, 25 indications), shallow
sequencing-based PGT sequencing in praismining interesting materials and the term in a single array in a comparison
to state-of-the-art GBS-based PGT for nuclear DNA (37 embryos, 18 families, 25 indications), shallow
sequencing-based PGT (10 e sequencing-based PGT (10 embryos, 3 families), and PCR-based PGT for mitochondrial DNA (10 embryos, 2 families), our approach alleviates technical limitations by decreasing whole genome amplification artifacts by 68.4%, in sequencing stated PCT (10 embryos) is cannot provided at the term of the intertmental DNA (10 embryos, 2 families), our approach alleviates technical limitations by decreasing whole genome amplification artifacts by 68.4%, emplification artifacts by 68.4%, increasing breadth of coverage by 4-fold, and reducing wet-lab turn-
around-time by 2.5-fold. Importantly, this method enables trio-based PGT-A for aneuploidy origin, an
approach we coin P approach we coin PGT-AO, detects translocation breakpoints, and nuclear and mitochondrial single
nucleotide variants and indels in base-resolution.
Keywords: pre-implantation genetic testing (PGT), whole genome sequencin nucleotide variants and indels in base-resolution.
 Keywords: pre-implantation genetic testing (PGT), whole genome sequencing (WGS), assisted

reproductive technologies (ART), haplotyping, haplarithmisis $\frac{1}{2}$ Keywords: pre-implantation genetic testing (PGT), whole genome sequencing (WGS), assisted
reproductive technologies (ART), haplotyping, haplarithmisis reproductive technologies (ART), haplotyping, haplarithmisis
 \mathbf{r}

Introduction

The Online Mendelian Inheritance in Man (OMIM) database lists over 4,700 genes with known
phenotype-causing mutations¹. Continuous advancements in sequencing technologies have
substantially broadened our understanding o phenotype-causing mutations⁺. Continuous advancements in sequencing technologies have
substantially broadened our understanding of genetic disorders^{2,3}, thereby increasing the potential
indications for preimplantation substantially broadened our understanding of genetic disorders^{2,3}, thereby increasing the potential
indications for preimplantation genetic testing (PGT) for monogenic disorders (PGT-M). Several
countries have initiated countries have initiated a population-wide offer of pre-conception carrier testing (PCT) for recessive
disease, increasing the number of carrier couples⁴⁻⁷. In addition, continuous increases in maternal⁸
and paternal disease, increasing the number of carrier couples⁴⁻⁷. In addition, continuous increases in maternal⁸
and paternal⁹ age, contribute to a higher risk for aneuploidies¹⁰, and *de novo* mutations¹¹ and
(segmental) c disease, increasing the number of carrier couples⁴. In addition, continuous increases in maternal⁹
and paternal⁹ age, contribute to a higher risk for aneuploidies¹⁰, and *de novo* mutations¹¹ and
(segmental) chro (segmental) chromosomal aberrations in offspring¹², respectively. These demographic factors, together with the growing list of identified genetic diseases-causing mutations¹³, contribute to an increased demand for rep age, contribute to a higher risk for aneuploidies²⁰, and *de novo* mutations²¹ and
thromosomal aberrations in offspring¹², respectively. These demographic factors,
the growing list of identified genetic diseases-cau (segmental) chromosomal aberrations in offspring²², respectively. These demographic factors,
together with the growing list of identified genetic diseases-causing mutations¹³, contribute to an
increased demand for repr together with the growing list of identified genetic diseases-causing mutations²⁵, contribute to an
increased demand for reproductive care, urging the need of scalable and generic genome-wide PGT
approaches.
PGT is an as

PGT is an assisted reproductive technology (ART), which is performed on DNA samples from
one- or few-cell biopsies from day-3 or day-5/6 in vitro fertilised (IVF) embryos, respectively. PGT
aims at selection of embryos una PGT
PGT
one- or few-
aims at selec
intrauterine Few-cell biopsies from day-3 or day-5/6 *in vitro* fertilised (IVF) embryos, respectively. PGT
selection of embryos unaffected from the genetic disorder in question or aneuploidies before
rine transfer, minimizing the nee aims at selection of embryos unaffected from the genetic disorder in question or aneuploidies before
intrauterine transfer, minimizing the need to contemplate pregnancy termination^{14,15}. Since its
inception in 1990¹⁶, intrauterine transfer, minimizing the need to contemplate pregnancy termination^{14,15}. Since its
inception in 1990¹⁶, PGT has evolved, encompassing non-hereditary genetic abnormalities i.e.
aneuploidies, affecting embr intrauterine transfer, minimizing the need to contemplate pregnancy termination^{44,45}. Since its
inception in 1990¹⁶, PGT has evolved, encompassing non-hereditary genetic abnormalities i.e.
aneuploidies, affecting embry inception in 1990¹⁰, PGT has evolved, encompassing non-hereditary genetic abnormalities i.e.
aneuploidies, affecting embryo implantation and viability via PGT for aneuploidies (PGT-A). Yearly,
70,000 PGT cycles are perfo 20,000 PGT cycles are performed globally¹⁷⁻²⁰, with PGT-A representing over half of these in Euope¹⁸.
PGT-A deems embryos harbouring any aneuploidies unsuitable for transfer. Despite randomised
controlled trials (RCTs 70,000 PGT cycles are performed globally²⁷ 20, with PGT-A representing over half of these in Euope²⁰.
PGT-A deems embryos harbouring any aneuploidies unsuitable for transfer. Despite randomised
controlled trials (RCTs) controlled trials (RCTs) casting doubt on the clinical utility of PGT-A²¹⁻²⁵, this PGT approach remains popular. Furthermore, there is a growing body of literature demonstrating the birth of healthy, euploid children af controlled trials (RCTs) casting doubt on the clinical utility of PGT-A²²²², this PGT approach remains
popular. Furthermore, there is a growing body of literature demonstrating the birth of healthy,
euploid children afte euploid children after the transfer of mosaic aneuploid embryos, as such the practise of discarding
these embryos is increasingly criticised^{26,27}. Existing whole genome sequencing PGT-A methods²⁸,
which rely on low-cov these embryos is increasingly criticised^{26,27}. Existing whole genome sequencing PGT-A methods²⁸,
which rely on low-coverage embryo sequencing, lack parental information and do not allow
determination of segregational o these embryos is increasingly criticised²⁰²². Existing whole genome sequencing PGT-A methods²⁰, which rely on low-coverage embryo sequencing, lack parental information and do not allow determination of segregational or determination of segregational origin of aneuploidies (*i.e.* whether it originates from meiosis or
mitosis). PGT-M is the second most common form of PGT¹⁸ and traditionally required designing
family- and locus-specific mitosis). PGT-M is the second most common form of PGT¹⁸ and traditionally required designing
family- and locus-specific assays, tailored for the genetic disorder within the family, causing a long
waiting list. While geno mitosis). PGT-M is the second most common form of PGT¹⁰ and traditionally required designing
family- and locus-specific assays, tailored for the genetic disorder within the family, causing a long
waiting list. While geno waiting list. While genome-wide haplotyping methods, such as Karyomapping²⁹, haplarithmisis³⁰⁻³²,
(S)Haploseek³³⁻³⁵, GENType³⁶ provided a generic approach and alleviated this problem, these
methods utilize SNP-geno waiting list. While genome-wide haplotyping methods, such as Karyomapping²⁵, haplarithmisis³⁰²²,
(S)Haploseek³³⁻³⁵, GENType³⁶ provided a generic approach and alleviated this problem, these
methods utilize SNP-genot (S)Haploseek³³⁻³⁵, GENType³⁸ provided a generic approach and alleviated this problem, these
methods utilize SNP-genotypes of only a fraction of the genome and require complex laboratory and
computational protocols. Cur computational protocols. Currently, a substantial proportion of PGT-M procedures still rely on
traditional approaches, such as PCR- or fluorescence in situ hybridisation (FISH)-based methods¹⁸.
Comprehensive chromosome s comprehensive protocols, such as PCR- or fluorescence in situ hybridisation (FISH)-based methods¹⁸.
Comprehensive chromosome screening methods, such as VeriSeq, enable the assessment of chromosomal abnormalities in PGT f traditional approaches, such as PCR- or fluorescence in situ hybridisation (FISH)-based methods²⁰.
Comprehensive chromosome screening methods, such as VeriSeq, enable the assessment of
chromosomal abnormalities in PGT fo chromosomal abnormalities in PGT for structural rearrangements (PGT-SR) with higher throughput chromosomal abnormalities in PGT for structural rearrangements (PGT-SR) with higher throughput

than traditional methods including FISH³⁷. Nonetheless, they cannot distinguish embryos with balanced translocations from those that are chromosomally normal³⁸, nor can they detect haploid or triploid embryos. Importan triploid embryos. Importantly, transferring an embryo carrying a balanced translocation perpetuates
the translocation, including the increased reproductive risk, to future generations. Another form of
PGT, known as PGT for the translocation, including the increased reproductive risk, to future generations. Another form of
PGT, known as PGT for mitochondrial disorders (PGT-MT), focuses on mutations in the mitochondrial
DNA (mtDNA) that contri perty known as PGT for mitochondrial disorders (PGT-MT), focuses on mutations in the mitochondrial
DNA (mtDNA) that contribute to the risk of inheriting a genetic mitochondrial disorder³⁹. These
mutations are exclusively PDNA (mtDNA) that contribute to the risk of inheriting a genetic mitochondrial disorder³⁹. These mutations are exclusively maternally inherited and are characterized by heteroplasmy, defined as the coexistence of normal DNA (mtDNA) that contribute to the risk of inheriting a genetic mitochondrial disorder³⁰. These
mutations are exclusively maternally inherited and are characterized by heteroplasmy, defined as the
coexistence of normal a mutations are entrancely materially material material entrodecessing y meta-polentally velocity coexistence of normal and mutated mtDNA. Clinical symptoms manifest only when the mutation load, the threshold of mutated mtDN load, the threshold of mutated mtDNA, surpasses a certain level. The mutation load inherited by
offspring can be highly variable due to bottleneck principles. PGT-MT allows for selection of embryos
carrying mutation loads offspring can be highly variable due to bottleneck principles. PGT-MT allows for selection of embryos carrying mutation loads below the pathogenic threshold³⁹, minimizing the likelihood of clinical manifestation of the a carrying mutation loads below the pathogenic threshold³⁹, minimizing the likelihood of clinical
manifestation of the associated mtDNA disorder. The current prevailing approach for PGT-MT
involves PCR-based method utilizi carrying mutation loads below the pathogenic threshold³⁹, minimizing the likelihood of clinical
manifestation of the associated mtDNA disorder. The current prevailing approach for PGT-MT
involves PCR-based method utilizi manifestation of the associated mts in associated meaning approach for PGT-MT within the same
laboratory workflow faces challenges due to limited availability of human data regarding the
representativeness of the mutation involves PCR-based method utilizing blastomere biopsy³⁵. The integration of PGT-MT within the same
laboratory workflow faces challenges due to limited availability of human data regarding the
representativeness of the mu laboratory representativeness of the mutation load in TE biopsies for the entire embryo. All presented challenges underscore the need to develop a universal PGT method that streamlines laboratory protocols and provides com challenges underscore the need to develop a universal PGT method that streamlines laboratory
protocols and provides comprehensive genome-wide coverage to address genetic disorders, even in
complex genomic loci.
We devised challenges underscore the need to accompt a universal PCP method that streamline interaction,
protocols and provides comprehensive genome-wide coverage to address genetic disorders, even in
complex genomic loci.
We devised

promplex genomic loci.

1999 We devised a simplified, scalable, and universal whole genome-sequencing-based method for

1997 (WGS-PGT) that enables all forms of PGT within a single assay. Here, we demonstrate that WGS-

19 We devised a s
PGT (WGS-PGT) that er
PGT enables (i) PGT for
and few-base pair gen The deviation a simplified, scalar in the simulation of general engineering interactions in SS-PGT) that enables all forms of PGT within a single assay. Here, we demonstrate that WGS-
bles (i) PGT for genetic indications i detection of the translocation breakpoints and inheritance of normal and derivative chromosomes, P_{GUT} and P_{GUT} is particular set P_{GUT} and P_{GUT} and single-detection of singleand few and few general families, (iii) a novel form of PCPT film and the PGT-AO, (iv) (in)direct
(meiotic vs. mitotic) of aneuploidies and their level of mosaicism, called PGT-AO, (iv) (in)direct
detection of the transloc (metal) detection of the translocation breakpoints and inheritance of normal and derivative chromosomes, allowing the distinction between normal embryos and balanced translocation carriers, and (v) PGT-
for mtDNA disorders allowing the distinction between normal embryos and balanced translocation carriers, and (v) PGT
for mtDNA disorders.
The metDNA disorders. $\begin{equation} \text{for mtDNA disorders.} \end{equation}$ for interval disorders.

Proof-of-concept for WGS-PGT

Proof-o
Proof-o
To estak
deep se
families To establish WGS for haplarithmisis-based PGT, we performed a pilot study in which we carried out deep sequencing (30-40X) to compare current clinical gold standard GBS-PGT (Fig. 1a) in two PGT families (family 1 and 2 wi then performed *in silico* subsampling at target coverages of 5X, 10X, 20X and 30X, to determine the optimal depth of coverage for accurate diagnosis. To this end, we evaluated several key parameters, families (family 1 and 2 with $n = 4$ embryos and $n = 2$ embryos, respectively) (Fig. 1b). The WGS
method allows for a 2.5-fold reduction in library preparation times compared to GBS (Fig. 1c). We
then performed *in silico* method allows for a 2.5-fold reduction in library preparation times compared to GBS (Fig. 1c). We
then performed *in silico* subsampling at target coverages of 5X, 10X, 20X and 30X, to determine the
optimal depth of covera optimal depth of coverage for accurate diagnosis. To this end, we evaluated several key parameters,
including breadth (Fig. 1d) and depth of coverage (Supplementary Fig. 1), Mendelian inconsistency
rates (Supplementary Fig including breadth (Fig. 1d) and depth of coverage (Supplementary Fig. 1), Mendelian inconsistency
rates (Supplementary Fig. 2) and haplotype concordance (Supplementary Fig. 3). WGS provided a 4-
fold higher breadth of cove Including breadth (Fig. 1d) and depth of coverage (Supplementary Fig. 1), Mendelian inconsistency
rates (Supplementary Fig. 2) and haplotype concordance (Supplementary Fig. 3). WGS provided a 4-
fold higher breadth of cove Fold higher breadth of coverage, i.e. the proportion of the genome that is sequenced, than GBS, with
WGS exhibiting a breadth of coverage exceeding 80% while GBS remains below 20%. Comparing
different depth of coverage le WGS exhibiting a breadth of coverage exceeding 80% while GBS remains below 20%. Comparing different depth of coverage levels revealed a significant difference in breadth of coverage between 5X and 10X ($P = 3.52 \times 10^{-3}$, different depth of coverage levels revealed a significant difference in breadth of coverage between 5X and 10X ($P = 3.52 \times 10^{-3}$, two-sided Wilcoxon's rank-sum), while increasing the depth of coverage from 10X to 20X did and 10X ($P = 3.52 \times 10^{-3}$, two-sided Wilcoxon's rank-sum), while increasing the depth of coverage
from 10X to 20X did not lead to a significant increase in breadth of coverage ($P = 8.31 \times 10^{-2}$, two-
sided Wilcoxon's ra and 10X ($P = 3.52 \times 10^{-3}$, two-sided Wilcoxon's rank-sum), while increasing the depth of coverage
from 10X to 20X did not lead to a significant increase in breadth of coverage ($P = 8.31 \times 10^{-2}$, two-
sided Wilcoxon's ra from 10X to 20X did not lead to a significant increase in breadth of coverage $(P = 8.31 \times 10^{-2}$, two-
sided Wilcoxon's rank-sum, **Fig. 1d**). The number of genome-wide informative SNPs increased 10-fold
for WGS-PGT at 10X for WGS-PGT at 10X coverage compared to GBS-PGT, reaching 2.5 million genome-wide informative SNPs (\pm 46,000 s.d.) (Supplementary Fig. 4a). Specifically, at 5X coverage there were 1.5 million genome-wide informative SN SNPs (\pm 46,000 s.d.) (Supplementary Fig. 4a). Specifically, at 5X coverage there were 1.5 million genome-wide informative SNPs (\pm 53,422 s.d.), whereas at 30X coverage, this number increased to 2.9 million (\pm 25, SNPs (± 46,000 s.d.) (Supplementary Fig. 4a). Specifically, at 5X coverage there were 1.5 million
genome-wide informative SNPs (± 53,422 s.d.), whereas at 30X coverage, this number increased to
2.9 million (± 25,960 s.d.) 2.9 million (± 25,960 s.d.). Typically, a higher number of genome-wide informative SNPs increases the accuracy and reliability of haplotype inference. For all target coverages, the mean genome-wide haplotype concordance b accuracy and reliability of haplotype inference. For all target coverages, the mean genome-wide
haplotype concordance between GBS and WGS was higher than 97%. Increasing the depth of
coverage from 10X to 20X, revealed no haplotype concordance between GBS and WGS was higher than 97%. Increasing the depth of
coverage from 10X to 20X, revealed no significant improvement (paternal haplotype $P = 0.59$ and
maternal haplotype $P = 0.70$, two-side coverage from 10X to 20X, revealed no significant improvement (paternal haplotype $P = 0.59$ and maternal haplotype $P = 0.70$, two-sided Wilcoxon's rank-sum, **Supplementary Fig. 3**). Furthermore, the mean Mendelian inconsi maternal haplotype $P = 0.70$, two-sided Wilcoxon's rank-sum, **Supplementary Fig. 3**). Furthermore, the mean Mendelian inconsistency rates representing WGA artefacts reduced substantially from 11.3% (\pm 1.26 s.d.) in GBS the mean Mendelian inconsistency rates representing WGA artefacts reduced substantially from 11.3% (\pm 1.26 s.d.) in GBS-PGT to 4.6% (\pm 1.35 s.d.) for WGS-PGT at 10X coverage (**Supplementary Fig. 2a**). Based on these 11.3% (\pm 1.26 s.d.) in GBS-PGT to 4.6% (\pm 1.35 s.d.) for WGS-PGT at 10X coverage (Supplementary Fig. 2a). Based on these findings, we settled that 10X sequencing provided sufficient data to reliably 2a). Based on these findings, we settled that 10X sequencing provided sufficient data to reliably
conduct haplarithmisis-based PGT-M.
To clinically validate WGS-PGT, we sequenced 31 embryo samples from 16 families at 10X c

Clinical validation of WGS-PGT

conduct happens made that the PCM
Clinical validation of WGS-PGT
To clinically validate WGS-PGT, we set
(Fig. 1b, Supplementary Table 1). (
|
(To clinically validation of the pathogenic variant of interest, was located PGT families that posed analytical
challenges when using GBS-PGT e.g. when the region of interest (ROI), representing the genomic
location of the (Fig. 1b, Supplementary Table 1). Specifically, we selected TGT families that posed analytical
challenges when using GBS-PGT e.g. when the region of interest (ROI), representing the genomic
location of the pathogenic varia location of the pathogenic variant of interest, was located in telomere regions, the family was consanguineous, the family had multiple genetic disorders, such as monogenic diseases and $\frac{1}{2}$ consanguineous, the family had multiple genetic disorders, such as monogenic diseases and
consanguineous, the family had multiple genetic disorders, such as monogenic diseases and consanguineous, the family had multiple genetic disorders, such as monogenic diseases and

translocations or when the embryo exhibited a haplotype recombination in proximity of the ROI. We observed a disparity in depth of coverage between Whole Genome Amplified (WGAed) embryo and bulk samples for GBS ($P = 1.43 \$ bulk samples for GBS ($P = 1.43 \times 10^{-3}$, two-sided Wilcoxon's rank-sum), which is likely attributed to the potential loss of restriction enzyme sites during amplification, leading to a lower library amount (Fig. 1e). However, in WGS, we found a similar depth of coverage between bulk DNA and WGAed samples, indicating a more sta **1e**). However, in WGS, we found a similar depth of coverage between bulk DNA and WGAed samples, indicating a more stable read out from WGS-PGT ($P = 0.46$, two-sided Wilcoxon's rank-sum). Results from the key parameters c 1e). However, in was, we found a similar depth of coverage between bulk DNA and WGAed samples,
indicating a more stable read out from WGS-PGT ($P = 0.46$, two-sided Wilcoxon's rank-sum). Results
from the key parameters cou from the key parameters could be replicated in these families, with a mean autosomal Mendelian
inconsistency rate of 2.42% (\pm 2.23 s.d.) for WGS and mean Mendelian inconsistency of 7.66% (\pm 2.33
s.d.) for GBS ($n = 3$ inconsistency rate of 2.42% (\pm 2.23 s.d.) for WGS and mean Mendelian inconsistency of 7.66% (\pm 2.33 s.d.) for GBS ($n = 31$ embryos) (**Fig. 1f**). The mean autosomal Mendelian inconsistency rate in the validation subs s.d.) for GBS ($n = 31$ embryos) (Fig. 1f). The mean autosomal Mendelian inconsistency rate in the validation subset demonstrated a lower rate than in the pilot study. This difference can be attributed to the specific char s.d.) for GBS (*n* = 31 embryos) (Fig. 11). The mean autosomal Mendelian inconsistency rate in the validation subset demonstrated a lower rate than in the pilot study. This difference can be attributed to the specific char to the specific characteristics of family 1, where all embryos had a translocation and two embryos
harboured an aneuploid chromosome (Supplementary Fig. 2a, Supplementary Table 4). Moreover,
the mean concordance of materna tharboured an aneuploid chromosome (Supplementary Fig. 2a, Supplementary Table 4). Moreover,
the mean concordance of maternal haplotypes was 97.8% (± 3.9 s.d.), and mean concordance of
paternal haplotypes was 99.0% (± 1.6 harboured an aneuploid chromosome (Supplementary Fig. 2a, Supplementary Table 4). Moreover,
the mean concordance of maternal haplotypes was 97.8% (\pm 3.9 s.d.), and mean concordance of
paternal haplotypes was 99.0% (\pm paternal haplotypes was 99.0% (\pm 1.6 s.d.) (Fig. 1g). One outlier was observed at 81.0% for maternal
haplotype concordance, originating from an embryo with a triploid genome. One of the diagnostic
criteria in the analy paternal haplotypes was 99.0% (\pm 1.6 s.d.) (Fig. 1g). One outlier was observed at 81.0% for inaternal
haplotype concordance, originating from an embryo with a triploid genome. One of the diagnostic
criteria in the anal eriteria in the analysis of an embryo for a specific monogenic indication include the number of
informative SNPs in a 4 Mb interval, *i.e.* 2 Mb up- and downstream of the mutation, are considered
on the maternally and/or p informative SNPs in a 4 Mb interval, *i.e.* 2 Mb up- and downstream of the mutation, are considered
on the maternally and/or paternally inherited haplotypes if these meet our assessment criteria
(Methods and Supplementary Informative SNPs in a 4 Mb interval, i.e. 2 Mb up- understanding the mutation, are considered

(Methods and Supplementary Table 2). Since we have deliberately selected challenging PGT families

with ROI in complex genomic (Methods and Supplementary Table 2). Since we have deliberately selected challenging PGT families
with ROI in complex genomic regions or high rates of consanguinity, in 13 out of 35 ROI the haplotype
concordance did not me (Methods and Supplementary Table 2). Since we have deliberately selected challenging PGT families
with ROI in complex genomic regions or high rates of consanguinity, in 13 out of 35 ROI the haplotype
concordance did not me concordance did not meet the assessment criteria in GBS-PGT (Supplementary Table 3). However, using WGS-PGT, in 5 out of the 13 ROIs, the assessment criteria could be met, owing to its inherent higher resolution. concordance did not meet the assessment criteria in GBS-PGT (Supplementary Table 3). However,
using WGS-PGT, in 5 out of the 13 ROIs, the assessment criteria could be met, owing to its inherent
higher resolution.
PGT-M wit using WGS-PGT, in 5 out of the 13 ROIs, the assessment criteria could be methydent criteria could be
higher resolution.
PGT-M is challenging when a close relative is unavailable for phasing, or in cases when prospective higher resolution.
PGT-M with the potential to directly detect pathogenic single nucleotide variants

|
|
|
|} PGT-M is challenging when a close relative is unavailable for phasing, or in cases
parents present with a *de novo* pathogenic single nucleotide variant (SNV).
pathogenic variant shows a promising alternative as it may fac parents present with a *de novo* pathogenic single nucleotide variant (SNV). Detection of the pathogenic variant shows a promising alternative as it may facilitate a diagnosis in these families.
While GBS approaches only c parents present with a de novo pantagent engits instrumentantly (stript 2 stream in the
pathogenic variant shows a promising alternative as it may facilitate a diagnosis in these families.
While GBS approaches only cover 2 While GBS approaches only cover 20% of the genome and enabled indirect detection monogenic
aberrations, WGS-PGT, at 10X depth of coverage, covers >80% of the genome (Fig. 1d), thereby
facilitating direct SNV detection. For Mheretions, WGS-PGT, at 10X depth of coverage, covers >80% of the genome (Fig. 1d), thereby
facilitating direct SNV detection. For 22 monogenic indications that included single base pair
substitutions or deletions, we comp facilitating direct SNV detection. For 22 monogenic indications that included single base pair
substitutions or deletions, we compared the genotypes and diagnoses ascertained from direct SNV
detection with those anticipat substitutions or deletions, we compared the genotypes and diagnoses ascertained from direct SNV detection with those anticipated based on the haplarithmisis result. Direct SNV detection provided the correct diagnosis in 9 detection with those anticipated based on the haplarithmisis result. Direct SNV detection provided
the correct diagnosis in 90% ($n = 20$) and correct genotype in 82% ($n = 18$) of the ROI (Fig. 2b,
Supplementary Fig. 6). W the correct diagnosis in 90% ($n = 20$) and correct genotype in 82% ($n = 18$) of the ROI (**Fig. 2b,**
Supplementary Fig. 6). When the number of reads at the ROI was higher than 5, the expected Supplementary Fig. 6). When the number of reads at the ROI was higher than 5, the expected Supplementary Fig. 6). When the number of reads at the ROI was higher than 5, the expected Supplementary Fig. 6). When the number of reads at the ROI was inglier than 5, the expected

genotype could be correctly identified in all cases. Remarkably, direct variant detection showed
promise in rare instances, resolving pathogenic SNVs in embryos with inconclusive haplarithmisis
results. Specifically, in em promise in results. Specifically, in embryo 23, which was assessed for an autosomal dominant pathogenic SNV,
the assessment criteria thresholds for haplarithmisis were not met (**Supplementary Table 2**),
resulting an inconc resulting an inconclusive diagnosis of the embryo. Direct variant detection showed presence of the
mutant allele at the ROI in 4 out of 5 reads, allowing embryo 23 to be classified as affected (Fig. 2b,
Supplementary Fig. the assessment enterm thresholds for haplantnimisis were not met (supplementary Table 2),
resulting an inconclusive diagnosis of the embryo. Direct variant detection showed presence of the
mutant allele at the ROI in 4 ou resulting an inconclusive angularity of the embryon channel assession income presence of the mutant allele at the ROI in 4 out of 5 reads, allowing embryo. 23 to be classified as affected (Fig. 2b, Supplementary Fig. 6). T **Supplementary Fig. 6**). To examine whether direct pathogenic variant detection could also be applied to larger deletions, we visualised indications representing deletions of two or more base pairs (*n* = 11). Deletions s Supplementary Fig. 6). To examine whether direct pathogenc variant detection could also be applied
to larger deletions, we visualised indications representing deletions of two or more base pairs (*n* =
11). Deletions span 11). Deletions spanning two or three base pairs could be identified within the integrated genomics
viewer software (IGV) ($n = 6$, **Supplementary Fig. 7a**). Bigger deletions presenting as autosomal
recessive pathogenic var viewer software (IGV) ($n = 6$, **Supplementary Fig. 7a**). Bigger deletions presenting as autosomal recessive pathogenic variants showed a loss of coverage ($n = 2$, **Supplementary Fig. 7b**), while bigger deletions presentin viewer software (IGV) ($n = 0$, Supplementary Fig. 7a). Bigger deletions presenting as autosomal
recessive pathogenic variants showed a loss of coverage ($n = 2$, **Supplementary Fig. 7b**), while bigger
deletions presenting deletions presenting as autosomal dominant or x-linked variants could be identified using the "view
as pairs" option in IGV in two affected embryos from family 7 and two unaffected embryos could be
confirmed (**Supplementar** as pairs" option in IGV in two affected embryos from family 7 and two unaffected embryos could be confirmed (Supplementary Fig. 7c). Furthermore, one aberrant embryo did not show the mutation as it has a mitotic trisomy wi confirmed (Supplementary Fig. 7c). Furthermore, one aberrant embryo did not show the mutation as
it has a mitotic trisomy with of the unaffected haplotype. Notably, the putative deletion could not be
detected directly in o it has a mitotic trisomy with of the unaffected haplotype. Notably, the putative deletion could not be
detected directly in one embryo (embryo 5 from family 2) which was a carrier of the deletion
(Supplementary Fig.7c). detected directly in one embryo (embryo 5 from family 2) which was a carrier of the deletion
(Supplementary Fig.7c).
PGT for aneuploidy origin (PGT-AO): a transformative PGT-A detected directly in one embryo (embryo 5 from family 2) which was a carrier of the deletion
(Supplementary Fig.7c).
PGT for aneuploidy origin (PGT-AO): a transformative PGT-A
Haplarithmisis-based WGS-PGT can accurately de

PGT for aneuploidy origin (PGT-AO): a transformative PGT-A

(Supplementary Fig.7c).
PGT for aneuploidy original
Haplarithmisis-based Wineiosis II, or mitosis, of |
|
|
| meiosis II, or mitosis, of aneuploidies and their degree of mosaicism (>10%) (Fig. 3a, Supplementary
Note Fig. 3a). Unlike meiotic trisomies, which involve both homologous chromosomes of the
contributing parent, mitotic tr meiosis ii, or mitosis, or aneuploidies and their degree or mosatcism (>10%) (Fig. 3a, Supplementary
Note Fig. 3a). Unlike meiotic trisomies, which involve both homologous chromosomes of the
contributing parent, mitotic tr Note Fig. 3a). Unlike meiotic trisomies, which involve both homologous chromosomes of the
contributing parent, mitotic trisomies result from the exact duplication of a single homologue.
Distinction between mitotic and meio Contribution between mitotic and meiotic II trisomy is possible when a crossover takes place on the chromosome of interest. The crossover rate for human chromosomes varies between 1.07 cM/Mb to 1.76 cM/Mb, ensuring that ea Chromosome of interest. The crossover rate for human chromosomes varies between 1.07 cM/Mb to 1.76 cM/Mb, ensuring that each chromosome generally experiences at least one crossover, while the actual number of crossovers de 1.76 cM/Mb, ensuring that each chromosome generally experiences at least one crossover, while the actual number of crossovers depends on the crossover rate and chromosome size⁴⁰. Distinction between mitotic and meiotic I 2.1.19 cm/mb, ensuring that each chromosome generally experiences at least one crossovers decided in that chromosome size⁴⁰. Distinction between mitotic and meiotic II trisomies is not possible in rare cases where there actual number of crossovers depends on the crossover rate and chromosome size⁴⁰. Distinction
between mitotic and meiotic II trisomies is not possible in rare cases where there is no crossover, or
when the crossover is lo

when the crossover is located in a challenging genomic region (e.g. telomeric or centromeric).
We identified 14 aneuploidies in 11 of 29 affected embryos analysed, encompassing 10 trisomies, 3
monosomies and 1 triploidy, w We identified 14 aneuploidies in 11 of 29 affected embryos analysed, encompassing 10 triso
monosomies and 1 triploidy, with some embryos carrying more than one aberratio
segregational origin could be determined for 10 out Monosomies and 1 triploidy, with some embryos carrying more than one aberration. The segregational origin could be determined for 10 out of 11 detected chromosomal gains (10 trisomies and 1 triploidy, **Supplementary Table** segregational origin could be determined for 10 out of 11 detected chromosomal gains (10 trisomies and 1 triploidy, Supplementary Table 4). Only a single embryo (Fig. 3b - embryo 18, family 7) did not have a crossover in the trisomic chromosome, precluding the differentiation between meiotic II and mitotic origins. Furthermore, we observed mosaic meiotic trisomies suggesting that a fraction of the mitotic origins. Furthermore, we observe that a fraction of the suggestion of the suggestion of the suggestion
The suggesting that a fraction of the suggestion of the suggestion of the suggestion of the suggestion of the
T

biopsied cells had undergone chromosomal rescue (**Supplementary Table 4**)²⁶. Three mosaic
aberrations with a meiotic origin were identified (**Supplementary Table 4**). These included two
embryos with a trisomy with a mos embryos with a trisomy with a mosaicism level of 80% and 90%. The third embryo had a genome-
wide triploidy with meiosis II origin and mosaicism level of 100% while chr15 was diploid with a
mosaicism level of 50%, suggest embry to the trisomy with a trisomy with a trisomy model of 100 mosaic zygosity. We further mosaicism level of 50%, suggesting that a fraction of the biopsied cells underwent chromosomal
rescue for chr15⁴¹. Additionally, the mosaicism level for 3 embryos with monosomy was determined
(100%, 100%, 45%). Mosaicism mosaicism is that a fraction of the biopsism level for 3 embryos with monosomy was determined
(100%, 100%, 45%). Mosaicism levels of 0% and 100% indicate a non-mosaic zygosity. We further
assessed nine aberrant embryos wit rescue for chr15⁴⁴. Additionally, the mosaicism level for 3 embryos with monosomy was determined
(100%, 100%, 45%). Mosaicism levels of 0% and 100% indicate a non-mosaic zygosity. We further
assessed nine aberrant embryo (100%). 100%, 100%, 100% incrementation of the material material intermentation application assessed nine aberrant embryos with copy number gains of known segregational origin to validate parents-only haplotyping and subse parents-only haplotyping and subsequent determination of segregational origin (Fig. 3c). In all cases
the segregational origin detected by parents-only haplarithmisis was concordant with standard
haplarithmisis. These resu parents-only haplotyping and subsequent determination of segregational origin (Fig. 3c). In all cases
the segregational origin detected by parents-only haplarithmisis was concordant with standard
haplarithmisis. These resu the segregational origin detected by parents-only insperimented that states and haplarithmisis. These results expand the possibilities of detecting segregational origin in human preimplantation embryos when no close relati haplarithmisis. These results expand the possibilities of detecting segregational origin in human
preimplantation embryos when no close relative is available.
PGT-SR with direct and indirect detection of translocation brea

PGT-SR with direct and indirect detection of translocation breakpoints

premiplantation embry of infinite the close relationship.
PGT-SR with direct and indirect detection of translocation b
Nine embryos from three families that underwent PGT-SR w
re-analysed using the WGS-PGT protocol. The co |
|
|
| re-analysed using the WGS-PGT protocol. The copy number state of all embryos could be correctly
determined with WGS-PGT and haplarithmisis purely by assessing the segmentation of the logR
values, which represent the log2 r re-and-
determined with WGS-PGT and haplarithmisis purely by assessing the segmentation of the logR
values, which represent the log2 ratio of the observed to expected copy number (Fig. 4,
Supplementary Fig. 8, Supplementar values, which represent the log2 ratio of the observed to expected copy number (Fig. 4, Supplementary Fig. 8, Supplementary Table 5). Although small duplications, such as the 1.08 Mb segmental duplication of chr16 in embry supplementary Fig. 8, Supplementary Table 5). Although small duplications, such as the 1.08 Mb
segmental duplication of chr16 in embryo 4 of family 1, were not segmented, such embryos could still
be correctly diagnosed bas Supplementary Fig. 8, Supplementary Table 5). Although small duplications, such as the 1.08 Mb
segmental duplication of chr16 in embryo 4 of family 1, were not segmented, such embryos could still
be correctly diagnosed bas sequental deletions and duplications remained consistent across all subsampled sequencing
depths, even at 5X coverage (Supplementary Fig. 8). In couples where embryos exhibited no copy-
number imbalances, the possibility o be correctly diagnosed based on the presence of the reciprocal deletion (Fig. 4). The identification of
these segmental deletions and duplications remained consistent across all subsampled sequencing
depths, even at 5X cov depths, even at 5X coverage (Supplementary Fig. 8). In couples where embryos exhibited no copy-
number imbalances, the possibility of inheriting either both normal homologues or both derivative
chromosomes (balanced transl depths, even at 5X coverage (Supplementary Fig. 6). In couples where embryos exhibited no copy-
number imbalances, the possibility of inheriting either both normal homologues or both derivative
chromosomes (balanced transl number inheriting the presiding struth is the mathematic space of inheriting
chromosomes (balanced translocation) from the carrier parent should be considered. Shallow
sequencing proves insufficient to distinguish between sequencing proves insufficient to distinguish between these cases. However, our haplarithmisis-based
PGT successfully identified embryos with unbalanced translocations. For these cases, the diploid
flanking haplotypes of t PGT successfully identified embryos with unbalanced translocations. For these cases, the diploid flanking haplotypes of the translocation allowed us to distinguish between normal and derivative chromosomes in all other emb Panking haplotypes of the translocation allowed us to distinguish between normal and derivative
chromosomes in all other embryos. Specifically, embryo 1 and 4 from family 1 were phased with an
unaffected sibling as a seed flanking happer, per in the transied unit allowed us to distinguish between normal and derivative
chromosomes in all other embryos. Specifically, embryo 1 and 4 from family 1 were phased with an
unaffected sibling as a see unaffected sibling as a seed for phasing. Haplotypes on the diploid side of the chromosomal
breakpoint were distinguished as either dark blue, indicating consistency with the reference
haplotype or light blue, indicating t breakpoint were distinguished as either dark blue, indicating consistency with the reference breakpeak were distinguished as either dark blue, indicating consisting consequently, embryo 1 inherited the
hormal chr8 and derivative chr16 while embryo 4 inherited the derivative chr8 and normal chr16 (Fig.
4). Importan happen, per entight blue, indicating the alternative implied, per central computing, embryo interferent inter-
normal chr8 and derivative chr16 while embryo 4 inherited the derivative chr8 and normal chr16 (Fig.
4). Import 4). Importantly, the paired-end sequencing data of the carrier parent and the embryos can be 4). Importantly, the paired-end sequencing data of the carrier parent and the embryos can be

leveraged to identify translocation breakpoints. In all carrier parents $(n = 3)$ included in this study, we could identify a breakpoint pair that closely corresponded to the expected translocation breakpoints ascertained u ascertained using karyotyping (**Supplementary Table 5,** sheet 1-3). Unlike the karyotyping results, the breakpoints derived from paired-end sequencing data could be determined at approximately base pair resolution, allowin breakpoints derived from paired-end sequencing data could be determined at approximately base pair resolution, allowing a more precise regions of interest to be defined for haplarithmisis. It is
important to note that the breakpoint locations obtained may exhibit variation among embryos, and
in some cases, multiple pair resolution, and ingle a more precise regions of interest to be defined its inpplementant foreing
important to note that the breakpoint locations obtained may exhibit variation among embryos, and
in some cases, multipl in some cases, multiple hits may be identified. Subsampled data from family 1 showed that a
minimum genome-wide depth of coverage of 10X is required to accurately call these breakpoints
(Supplementary Table 5, sheet 1). We in some cases, maniped and may be cased may be identified and mean random family 2 showed may be
minimum genome-wide depth of coverage of 10X is required to accurately call these breakpoints
(Supplementary Table 5, sheet 1 Supplementary Table 5, sheet 1). We could identify corresponding breakpoint pairs in six of the
eight unbalanced embryos from families 1 and 19. The two embryos in which no breakpoints were
identified both inherited a deri (Supplementary Table 5, sheet 1). We could identify corresponding breakpoint pairs in six of the
eight unbalanced embryos from families 1 and 19. The two embryos in which no breakpoints were
identified both inherited a der eight unbanded embry of the tunnel embryon the two embry of the the temperature and identified both inherited a derivative chr8 carrying the small segment of chr16 (1.08Mb). Although paired-end sequencing analysis did not paired-end sequencing analysis did not identify a breakpoint pair in embryo 23 of family 9, which
could be attributable to a chaotic copy number profile (Supplementary Table 5, sheet 4), we could
correctly identify the rel paired state equencing analysis did note that in the setting pair in the unit f is the main of pair in could
correctly identify the relevant breakpoint pair in the unbalanced embryos 24 and 25. For the paternal
ins(10;7) correctly identify the relevant breakpoint pair in the unbalanced embryos 24 and 25. For the paternal
ins(10;7) of family 19 (**Supplementary Table 5, sheet 2**), one would expect to find a single breakpoint
on chr10 and two ins(10;7) of family 19 (**Supplementary Table 5, sheet 2**), one would expect to find a single breakpoint
on chr10 and two corresponding breakpoints on chr7, specifically a position on the q arm of chr7 and
the end of chr7. ins(10;7) of family 19 (Supplementary Table 5, sheet 2), one would expect to find a single breakpoint
on chr10 and two corresponding breakpoints on chr7, specifically a position on the q arm of chr7 and
the end of chr7. H on christ and the corresponding a campeline on chris, a position, a position on the Alanta didentify breakpoint pairs from between chr10 and chr7 in the carrier parent, the chr10 coordinates do not match the findings from the end of contribution of the end of chrate in the carrier parent, the chr10 coordinates
do not match the findings from the diagnostic karyotyping and only one corresponding chr7 position
was identified which lies in the identified which lies in the diagnostic karyotyping and only one corresponding chr7 position
was identified which lies in the centre of the expected inserted segment. Whether the same
breakpoints would be found in unbalanc do not match the matter includings from the angular maty expected inserted segment. Whether the same
breakpoints would be found in unbalanced embryos could not be assessed as neither of the
unbalanced embryos, embryos 38 a breakpoints would be found in unbalanced embryos could not be assessed as neither of the unbalanced embryos, embryos 38 and 39, inherited the derivative chr10. Based on the segmented breakpoints would be derivative for the found in unbalanced embryos, embryos 38 and 39, inherited the derivative chr10. Based on the segmented logR information from Haplarithmisis conducted on embryos 38 and 39, it was how logR information from Haplarithmisis conducted on embryos 38 and 39, it was however possible to
determine that the chr7 breakpoint would be around 129,135,000 bp, which is in keeping with the
findings from the diagnostic k determine that the chr7 breakpoint would be around 129,135,000 bp, which is in keeping with the findings from the diagnostic karyotyping of the father.

PGT for mitochondrial DNA disorders

The current gold standard for PGT for mtDNA disorders (PGT-MT) requires a specialised PCR-based restriction fragment length polymorphism (PCR-RFLP) workflow that is carried out on a day-3 |
|
|
| The current gold standard for PGT for measure (PGT-MT) requires a specified out on a day-3

blastomere biopsy³⁹. We compared the heteroplasmy levels from the blastomere biopsy to

heteroplasmy levels obtained by applyin blastomere biopsy³⁹. We compared the heteroplasmy levels from the blastomere biopsy to
heteroplasmy levels obtained by applying the same protocol to day-5 trophectoderm (TE) biopsies (*n*
= 4, **Fig. 1b**) and found that blastomere biopsy³⁹. We compared the heteroplasmy levels from the blastomere biopsy to
heteroplasmy levels obtained by applying the same protocol to day-5 trophectoderm (TE) biopsies (*n*
= 4, **Fig. 1b**) and found that t heteroplasmy levels obtained by the same protocol to day 3 trophectoderm (TE) shepset (n
= 4, Fig. 1b) and found that the heteroplasmy levels differed by 1% to 4% (Fig. 5a). Furthermore, the
PCR-RFLP protocol applied to t = 4, Fig. 1b) and found that the heteroplasmy levels differed by 1% to 4% (Fig. 5a). Furthermore, the
PCR-RFLP protocol applied to the corresponding DNA derived from the surplus embryos, i.e. the
remaining embryo, yielded remaining embryo, yielded heteroplasmy levels that differed by 0% to 4% and 1% to 3% to the day-3 remaining embryo, yielded heteroplasmy levels that differed by 0% to 4% and 1% to 3% to the day-3

day-5 TE biopsies ($n = 4$), and DNA derived from the corresponding surplus embryo material, *i.e.* 100-
200 cells, with a target genome-wide sequencing depth of 30X (**Fig. 1b**). The mitochondrial genome
was highly covered day the biopsies (n = 1), and DIM corresponding to the corresponding corpus than 1, and DIM derived from the 200 cells, with a target genome-wide sequencing depth of 30X (Fig. 1b). The mitochondrial genome was highly cover was highly covered at all levels of subsampling with only one site being covered less than 100 times in
the TE-biopsy data after subsampling to 10X coverage (Fig. 5b). Importantly, 105 mtDNA sites with
known pathogenic va the TE-biopsy data after subsampling to 10X coverage (Fig. 5b). Importantly, 105 mtDNA sites with
known pathogenic variants had a minimum coverage of 1,944X in the 10X subsampled TE-biopsy data
 $(n = 4)$ (Supplementary Fig. the TE-biopsy data after subsampling to 10X coverage (Fig. 3b). Importantly, 105 mtDNA sites with
known pathogenic variants had a minimum coverage of 1,944X in the 10X subsampled TE-biopsy data
($n = 4$) (Supplementary Fig ($n = 4$) (Supplementary Fig. 9). To assess reproducibility of our PGT-MT approach, we calculated the mitochondrial genome coverage of the samples sequenced at 10X for PGT-MT ($n = 2$) or PGT-M and PGT-SR ($n = 23$) indicati (n = 4) (Supplementary Fig. 9). To assess reproducibility of our PGT-MT approach, we calculated the
mitochondrial genome coverage of the samples sequenced at 10X for PGT-MT $(n = 2)$ or PGT-M and
PGT-SR $(n = 23)$ indications PGT-SR ($n = 23$) indications and found that the coverage across all WGAed embryo samples was
comparable (two sites with coverage under 100X in any sample, minimum coverage of any
pathogenic variants site 826X in any sampl Comparable (two sites with coverage under 100X in any sample, minimum coverage of any pathogenic variants site 826X in any sample) (Fig. 5b, Supplementary Fig. 9). Compared to the heteroplasmy levels elucidated from the d pathogenic variants site 826X in any sample) (Fig. 5b, Supplementary Fig. 9). Compared to the
heteroplasmy levels elucidated from the day-3 biopsies by PCR-RFLP, the day-5 10X WGS-PGT results
varied by 1.5% lower to 3.3% h heteroplasmy levels elucidated from the day-3 biopsies by PCR-RFLP, the day-5 10X WGS-PGT results
varied by 1.5% lower to 3.3% higher (Fig. 5a). Subsampling the sequencing data had little effect on
the calculated heteropla heteroplasmy levels and the day-3 biopsimum in the day-3 biopsis varied by 1.5% lower to 3.3% higher (Fig. 5a). Subsampling the sequencing data had little effect on the calculated heteroplasmy levels with estimates varying varied by 1.5% lower to 3.5% higher (Fig. 3a). Subsampling the sequencing data had little effect on
the calculated heteroplasmy levels with estimates varying up to a maximum of 1.6% in any sample at
different levels of gen different levels of genome-wide coverage (Supplementary Table 6-7). The subsampled 10X WGS-PGT
heteroplasmy levels from the surplus embryo were 0% to 3.6% higher compared to the day-3 biopsy
and between 1.6% lower and 1.5% different levels of genome-wide coverage (Supplementary Table 6-7). The subsampled 10X WGS-TGT
heteroplasmy levels from the surplus embryo were 0% to 3.6% higher compared to the day-3 biopsy
and between 1.6% lower and 1.5% and between 1.6% lower and 1.5% higher compared to the day-5 biopsy (Fig. 5a, Supplementary
Table 6-7). Similarly, when TE biopsy and surplus embryo were sequenced directly at 10X ($n = 2$, Fig.
1b), the heteroplasmy level Table 6-7). Similarly, when TE biopsy and surplus embryo were sequenced directly at $10X$ ($n = 2$, Fig. 1b), the heteroplasmy levels obtained for PCR-RFLP on day 3 differed by 4% from WGS TE biopsy result and there was a **1b**), the heteroplasmy levels obtained for PCR-RFLP on day 3 differed by 4% from WGS TE biopsy result and there was a 1 to 1.8% difference between WGS results from the TE biopsy and the surplus embryo material (Fig. 5a, 1b), the heteroplasmy levels obtained for PCR-RFLP on day 3 differed by 4% from WGS TE biopsy
result and there was a 1 to 1.8% difference between WGS results from the TE biopsy and the surplus
embryo material (Fig. 5a, Sup result and there was a 1 to 1.8% and there is 1.8% difference between Westerman them the TE biopsy with PCR-
embryo material (Fig. 5a, Supplementary Table 8). In two cases, where the day 3 biopsy with PCR-
RFLP did not yie embryo material (Fig. 5a, Supplementary Table 8). In two cases, where the day 3 biopsy with PCR-
RFLP did not yield a result, a heteroplasmy level could be obtained using WGS-PGT. RFLP did not yield a result, a heteroplasmy level could be obtained using WGS-PGT.

Discussion

outperforms traditional and state-of-the-art PGT technologies (Fig. 6). The advent of SNP-array and
GBS-based PGT methodologies enabled generic assays, but these approaches still faced challenges in
complex genomic regions outperforms traditional and state of the art PGT technologies (Fig. 0). The advent of SNP-array and
GBS-based PGT methodologies enabled generic assays, but these approaches still faced challenges in
complex genomic regions complex genomic regions, e.g. telomeres and centromeres, in consanguineous couples, and when
there is haplotype recombination in proximity of the ROI. The increased resolution through WGS-PGT
allowed more embryo samples to complex genomic regions, e.g. terms is and centromeres, in centromganised couplex, and when
there is haplotype recombination in proximity of the ROI. The increased resolution through WGS-PGT
allowed more embryo samples to allowed more embryo samples to meet the diagnostic assessment criteria thresholds in these
complex genomic regions for PGT-M. In parallel, PGT-M via haplotyping can be complemented with
direct pathogenic variant detection. complex genomic regions for PGT-M. In parallel, PGT-M via haplotyping can be complemented with
direct pathogenic variant detection. WGS-PGT enabled parents-only PGT-AO by identifying
aneuploidies, their segregational and p direct pathogenic variant detection. WGS-PGT enabled parents-only PGT-AO by identifying
aneuploidies, their segregational and parental origin and level of mosaicism without the need of an
available close-relative for phasi aneuploidies, their segregational and parental origin and level of mosaicism without the need of an
available close-relative for phasing. We demonstrate the ability to detect structural rearrangements
and distinguish norma and distinguish normal from balanced embryos through both a direct structural rearrangements
and distinguish normal from balanced embryos through both a direct approach, leveraging paired-
end sequencing information from t and distinguish normal from balanced embryos through both a direct approach, leveraging paired-
end sequencing information from the embryo samples, and an indirect approach, which involves
analyzing flanking haplotypes. E and distinguish normal from both a distinguish both a distinguish both a direct approach and pair and pair and analyzing flanking haplotypes. Even though various strategies exist to differentiate normal from
balanced embryos, including MaReCs⁴², a method based on shallow sequencing⁴³, and a method
based on Nanopore sequencing t balanced embryos, including MaReCs⁴², a method based on shallow sequencing⁴³, and a method
based on Nanopore sequencing technology⁴⁴, they cannot be integrated with other workflows for
other PGT purposes as each wor balanced embryos, including MaReCs⁴², a method based on shallow sequencing⁴², and a method
based on Nanopore sequencing technology⁴⁴, they cannot be integrated with other workflows for
other PGT purposes as each work based on Nanopore sequencing technology⁴⁴, they cannot be integrated with other workflows for
other PGT purposes as each workflow requires different technologies. Finally, we show the
comparability and reproducibility of comparability and reproducibility of heteroplasmy levels between traditional day-3 blastomere biopsy
with PCR-RFLP and our WGS-PGT method. We demonstrate that all mtDNA positions in the samples
sequenced at 10X coverage ha with PCR-RFLP and our WGS-PGT method. We demonstrate that all mtDNA positions in the samples
sequenced at 10X coverage have a mtDNA coverage of more than 100X except for one site. While
prior studies have demonstrated the with PLA-RFLP and our PLA-RFLP members of more than 100X except for one site. While
prior studies have demonstrated the ability to identify mtDNA variants and heteroplasmy levels from
WGS-data^{45,46}, integrating these int prior studies have demonstrated the ability to identify mtDNA variants and heteroplasmy levels from
WGS data^{45,46}, integrating these into an all-in-one PGT method is an important step forward that
makes PGT scalable and prior studies have demonstrated the ability of the ability in term cannot and heteroplasmy levels form.
WGS data^{45,46}, integrating these into an all-in-one PGT method is an important step forward that
makes PGT scalable

makes PGT scalable and accessible.
A key feature of WGS-PGT is the ability to directly detect the pathogenic variant of interest.
Direct variant detection can complement haplarithmisis by resolving uncertain or inconclusiv A key feature of WGS-PGT
Direct variant detection can com
findings and by offering a solution i
suitable close relative for phasing i: A key feature of WGS-PGT is the ability of MCS-PGT ine pathogenic running contains the method
variant detection can complement haplarithmisis by resolving uncertain or inconclusive
and by offering a solution in families wi Findings and by offering a solution in families with a *de novo* variant in one of the parents or when a suitable close relative for phasing is unavailable. In all cases where the depth of coverage exceeded 5X, we could co suitable close relative for phasing is unavailable. In all cases where the depth of coverage exceeded
5X, we could correctly detect the SNV. A prior study that conducted WGS on embryos to identify *de*
novo pathogenic va 5X, we could correctly detect the SNV. A prior study that conducted WGS on embryos to identify *de*
novo pathogenic variants for known diseases and polygenic risk score analysis⁴⁶ did not account for
allelic dropout or d 5X, we could correctly detect the SNV. plusted way that conducted WGS on embry of the linew, and now pathogenic variants for known diseases and polygenic risk score analysis⁴⁶ did not account for allelic dropout or dropnovo pathogenic variants for known diseases and polygenic risk score analysis³⁶ did not account for allelic dropout or drop-in issues related to amplification as they did not include parental sequencing information in th allelic drop-in their analysis. An advantage of our method is that it can be performed both in a direct
and indirect fashion using haplarithmisis principles, to be certain of our pathogenic variant of
interest.
Apart from information indirect fashion using haplarithmisis principles, to be certain of our pathogenic variant of
interest.
Apart from the primary objective of PGT-A – *i.e.* prioritising embryos with the highest
implantation poten

interest.
Apart from the primary objective of PGT-A – *i.e.* prioritising embryos with the highest م
implanta
. Apart from the primary objective of PGT-AO, which determines the segregational origin of a prioritial – we introduced PGT-AO, which determines the segregational origin of implantation potential – we introduced PGT-AO, which determines the segregational origin of

an empression and the divergence between the objectives of selecting a chromosomally euploid embryo or
an embryo with the highest implantation potential for transfer. Importantly, our approach permits the
analysis of haplo an embryo with the highest implantation potential for transfer. Importantly, our approach permits the analysis of haploid or triploid embryos and embryos with meiotic aneuploidies, particularly those involving chromosomes analysis of haploid or triploid embryos and embryos with meiotic aneuploidies, particularly those
involving chromosomes assessed in non-invasive prenatal testing $(NIPT)^{47}$. Mitotic aneuploid embryos
are often mosaic and involving chromosomes assessed in non-invasive prenatal testing (NIPT)⁴⁷. Mitotic aneuploid embryos
are often mosaic and the abnormality may not be uniformly distributed throughout the blastocyst⁴⁸⁻
⁵¹. Furthermore, involving chromosomes assessed in non-invasive prenatal testing (NIPT)". Mitotic aneuploid embryos
are often mosaic and the abnormality may not be uniformly distributed throughout the blastocyst^{48-
⁵¹. Furthermore, prev} are often mosaic and the abnormality may not be uniformly distributed throughout the blastocyst⁻⁰
⁵¹. Furthermore, previous studies have shown that mosaic embryos can result in healthy offspring^{26,27},
and chromosomal ²². Furthermore, previous studies have shown that mosaic embryos can result in healthy offspring^{20,27},
and chromosomal mosaicism may disappear via a self-correction mechanism where aneuploid cells
are depleted in the are depleted in the inner cell mass and remain present in the TE lineage⁵². Current copy number
quantitation methods fail to differentiate between true mosaic embryos and uniformly euploid or
aneuploid embryos with techn are depleted in the inner cell mass and remain present in the TE lineage²⁴. Current copy number
quantitation methods fail to differentiate between true mosaic embryos and uniformly euploid or
aneuploid embryos with techn aneuploid embryos with technical noise⁵³. These findings underscore the importance of assessing the parental and segregational origin of aneuploidies besides the degree of mosaicism. The ability of PGT-AO to select an em parental and segregational origin of aneuploidies besides the degree of mosaicism. The ability of PGT-
AO to select an embryo without meiotic aneuploidies, most likely helps couples from the difficult
decision of potential parent or and spionales implantation and viable pregnancy outcomes. This impovation faises ethical, decision of potentially terminating a pregnancy of a foetus with a chromosomal aberration⁵⁴.
Longitudinal non-selection studies are needed to explore the connection between the segregational
origin of aneuploidies implan decision of potentially terminating a pregnancy of a foetus with a chromosomal aberration⁵⁴.
Longitudinal non-selection studies are needed to explore the connection between the segregational
origin of aneuploidies implan Longin of aneuploidies implantation and viable pregnancy outcomes. This innovation raises ethical,
legal, and social issues that need further reflection (**Supplementary Note ELSI**)
Our WGS-PGT method also have some limitat

legal, and social issues that need further reflection (**Supplementary Note ELSI**)
Our WGS-PGT method also have some limitations. The coverage levels may not
suffice for accurate *de novo* pathogenic variants detection, whi legal, and social issues that need further reflection (Supplementary Note ELSI)
Our WGS-PGT method also have some limitations. The cover
suffice for accurate *de novo* pathogenic variants detection, which is recommen
addre Our accurate *de novo* pathogenic variants detection, which is recommended to be 30-40X⁵⁵. To
this, we propose increasing depth of coverage to 30X when there is a *de novo* pathogenic
in the parents. The genome-wide Mend address this, we propose increasing depth of coverage to 30X when there is a *de novo* pathogenic
variant in the parents. The genome-wide Mendelian inconsistency rate of 2.42%, representing both
amplification errors, seque variant in the parents. The genome-wide Mendelian inconsistency rate of 2.42%, representing both amplification errors, sequencing errors and putative *de novo* pathogenic variants. Notably, when specifically examining bulk amplification errors, sequencing errors and putative *de novo* pathogenic variants. Notably, when
specifically examining bulk samples from trios, others have observed Mendelian inconsistency rates
of 1.92%⁵⁶. These numb specifically examining bulk samples from trios, others have observed Mendelian inconsistency rates
of 1.92%⁵⁶. These numbers highly exceed the average rate of *de novo* pathogenic variants of
1.20 $\text{Im}\sqrt{210^{-8}}$ per nuc specifically exceed the average rate of *de novo* pathogenic variants of 1.92%⁵⁶. These numbers highly exceed the average rate of *de novo* pathogenic variants of 1.20 Dx per nucleotide per generation (~0.3% per ge 1.20 $\text{m} \times \text{m}$ 10⁻⁸ per nucleotide per generation (~0.3% per generation)⁵⁷, probably attributable to sequencing errors. Longitudinal validation of the direct pathogenic variant detection is essential. Although inco 1.202×210 ° per nucleotide per generation (~0.3% per generation)", probably attributable to
sequencing errors. Longitudinal validation of the direct pathogenic variant detection is essential.
Although incorporating PGT-MT sequencing errors. Longitudinal validation of the direct pathogenic validation of WGS-PGT for mtDNA disorders on day-5 biopsies due to the limited sample size of PGT-MT families.
Another limitation of our method and PGT in Another limitation of our method and PGT in general is the need for embryo biopsy, as biopsy
procedures demand specialised technical expertise, costly equipment and might impede embryo
viability. In response, developments Another limitation of our method and PGT in general is the need for embryo biopsy, as biopsy
procedures demand specialised technical expertise, costly equipment and might impede embryo
viability. In response, developments procedures demand specialised technical expertise, costly equipment and might impede embryo viability. In response, developments in the field of PGT have focused on utilising non-invasive DNA sources like cfDNA in the spen procedures demand specialism in the field of PGT have focused on utilising non-invasive DNA
sources like cfDNA in the spent culture medium⁵⁸ that originates from inner cell mass, TE cells⁵⁹,
cumulus cells, and polar bo sources like cfDNA in the spent culture medium⁵⁸ that originates from inner cell mass, TE cells⁵⁹, cumulus cells, and polar bodies⁶⁰. Potential contamination from cells or maternal origin should be assessed in futur cumulus cells, and polar bodies⁶⁰. Potential contamination from cells or maternal origin should be assessed in future methods. Haplarithmisis can distinguish between contributions from maternal and assessed in future methods. Haplarithmisis can distinguish between contributions from maternal and α

fetal genomes in placental DNA samples⁵², therefore our WGS-PGT method could be used to tackle
the maternal contamination and thus WGS-PGT is future-proof for development of niPGT.
In summary, we have presented a new str In summary, we have presented a new strategy for all-in-one PGT that is able to capture
PGT into one method. WGS-PGT enables a simplified, scalable, and universal PGT that c
current state-of-the-art PGT methods and has the |
|
| PGT into one method. WGS-PGT enables a simplified, scalable, and universal PGT that outperforms
current state-of-the-art PGT methods and has the capacity to enhance reproductive genetic care. PET into one members into one manner a simplified, scalarly, and simplified is that outperforms
current state-of-the-art PGT methods and has the capacity to enhance reproductive genetic care.
Acknowledgements
We are gratef

Acknowledgements

Extrement of the art Polymontal and has the capacity of enhance reproductive genetic care.
Acknowledgements
(Erfelijkheid Voortplanting & Aanleg) specialty program (grant no. KP111513), the Horizon Eur ノ
|
| (Erfelijkheid Voortplanting & Aanleg) specialty program (grant no. KP111513), the Horizon Europe
(NESTOR, grant no. 101120075) of the European Commission and the Horizon 2020 innovation (ERIN,
grant no. EU952516) grants. W (NESTOR, grant no. 101120075) of the European Commission and the Horizon 2020 innovation (ERIN, grant no. EU952516) grants. We would like to specially thank F.J.M. Snepvangers, L.E.C. Meers, W. Loneus, K. Daenen, S. Spiert (NESTOR), gram AP CELECTOR, PEACE EARLY DEATHER IN AN APPLY AND NONETHER IN (EARLY)
grant no. EU952516) grants. We would like to specially thank F.J.M. Snepvangers, L.E.C. Meers, W.
Loneus, K. Daenen, S. Spierts, B.M. Reut grant nor European, S. Spierts, B.M. Reuters and M. Kurvers-Alofs for their support with all clinical
wet-lab related procedures. Also, we would like to thank R.C. Derks from the Radboudumc Genome
Technology Center for WGS London: The Units of the Stadboudum Genome
Technology Center for WGS data generation.
Competing Interests Technology Center for WGS data generation.
Competing Interests
M.Z.E. is co-inventor on patent applications: ZL910050-PCT/EP2011/ 060211-WO/2011/157846

Competing Interests

Competing Interests
M.Z.E. is co-inventor on patent application.
"Methods for haplotyping single cells" $\frac{1}{2}$ 'Methods for haplotyping single cells' and ZL913096-PCT/EP2014/068315-WO/2015/028576
'Haplotyping and copy-number typing using polymorphic variant allelic frequencies'. 'Maplotyping and copy-number typing using polymorphic variant allelic frequencies'.
'Maplotyping and copy-number typing using polymorphic variant allelic frequencies'. 'Haplotyping and copy-number typing using polymorphic variant allelic frequencies'.

-
- ار /
1. McKusick-Online of Genetic Mext-Generation Sequencing Technology: Current Trends and Advancements. *Biology* OMIM®. (2022). 2. Satam, H., et al. Next-Generation Sequencing Technology: Current Trends and Advancements. Biology
12, 997 (2023).
3. Mastrorosa, F.K., Miller, D.E. & Eichler, E.E. Applications of long-read sequencing to Mendelian
- 1. McK
2. Sata
2. Sata
12, Mas
3. Mas
gene 12, 997 (2023).
Mastrorosa, F.I
genetics. *Genor*. 3. genetics. *Genome Medicine* 15, 42 (2023).
3. Sallevelt, S., *et al.* Diagnostic exome-based preconception carrier testing in consanguineous couples:
- genetics. Genome Medicine 15, 42 (2023).
Sallevelt, S., *et al.* Diagnostic exome-base
results from the first 100 couples in clinica 4. Sallevelt, S., et al. Diagnostic exome-based preconception carrier testing in consanguineous couples.
The sallevelt, S.C.E.H., de Koning, B., Szklarczyk, R., Paulussen, A.D.C., de Die-Smulders, C.E.M. & Smeets,
- results from the first 100 couples in clinical practice. Genet Med 23, 1125-1136 (2021).
Sallevelt, S.C.E.H., de Koning, B., Szklarczyk, R., Paulussen, A.D.C., de Die-Smulders, C.
H.J.M. A comprehensive strategy for exome-5. Sallevelt, S.C.E.H., de Koning, B., Szklarczyk, R., Paulussen, A.D.C., de Die-Smulders, C.E.M. & Smeets,
H.J.M. A comprehensive strategy for exome-based preconception carrier screening. *Genetics in*
Medicine **19**, 583-H.J.M. A comprehensive strategy for exome-based preconception carrier screening. Genetics in
Medicine 19, 583-592 (2017).
Van Steijvoort, E., *et al.* Interest in expanded carrier screening among individuals and couples in
- Medicine 19, 383-592 (2017).
Van Steijvoort, E., *et al.* Inter
general population: systemati 6. Van Steijvoort, E., et al. Interest in expanded carrier screening among mandadis and couples in the general population: systematic review of the literature. Hum Reprod Update 26, 335-355 (2020).
7. Zhang, T., *et al.* E
- general population: systematic review of the literature. Hum Reprod Opdute 26, 333-335 (2020).
Zhang, T., *et al.* Expanded Preconception Carrier Screening in Clinical Practice: Review of Techn
Guidelines, Implementation C 7. Zhang, T., *et al.* Expanded Preconception Carrier Screening in Clinical Practice: Review of Technology,
Guidelines, Implementation Challenges, and Ethical Quandaries. *Clin Obstet Gynecol* 62, 217-227
(2019).
B. Eurost Guidelines, Implementation Challenges, and Ethical Quandaries. Clin Obstet Gynecol **62**, 217-227
(2019).
Eurostat. Women are having their first child at an older age. Vol. 2023 News article about the
- .
Eurosta
Increasi increasing mean age of women in the European Union (Eurostat,
https://ec.europa.eu/eurostat/web/products-eurostat-news/-/ddn-20200515-2, 2020).
8. Khandwala, Y.S., Zhang, C.A., Lu, Y. & Eisenberg, M.L. The age of fathers i increasing mean and the European age of the European age of the European Attps://ec.europa.eu/eurostat/web/products-eurostat-news/-/ddn-20200515-2, 2020).
Khandwala, Y.S., Zhang, C.A., Lu, Y. & Eisenberg, M.L. The age of f
- https://ec.eurostat.com/indextate/metal/metal/metal/metal/metal/metal/metal/metal/metal/metal/metal/metal/meta
https://ddn-20200515-2020051-202015. Hum Reprod 32, 2110-2116 (2017). of 168 867 480 births from 1972 to 2015. Hum Reprod 32, 2110-2116 (2017).
10. Gruhn, J.R., *et al.* Chromosome errors in human eggs shape natural fertility over reproductive life
- of 168 867 480 births from 1972 to 2019. *Hum Reprod 32, 2110-2110 (2017)*.
Gruhn, J.R., *et al.* Chromosome errors in human eggs shape natural fertili
span. Science **365**, 1466-1469 (2019). 10. Gruhn, J.R., et al. Chromosome errors in human eggs shape natural fertility over reproductive life
span. Science 365, 1466-1469 (2019).
11. Rahbari, R., et al. Timing, rates and spectra of human germline mutation. Nat
- span. Science 365, 1466-1469 (2019).
Rahbari, R., *et al.* Timing, rates and (2016). 11. Rahbari, R., et al. Timing, rates and spectra of human germine mutation. Nat Genet 48, 126-133
(2016).
12. Sloter, E.D., *et al.* Frequency of human sperm carrying structural aberrations of chromosome 1
- 、
Sloter,
increase 12. Sloter, E.D., et al. Frequency of human sperm carrying structural aberrations of emoniosome 1
increases with advancing age. Fertility and Sterility 87, 1077-1086 (2007).
13. Amberger, J.S., Bocchini, C.A., Scott, A.F.
- increases with advancing age. Fertility and Sterlity 87, 1077-1086 (2007).
Amberger, J.S., Bocchini, C.A., Scott, A.F. & Hamosh, A. OMIM.org: I
phenotype-gene relationships. Nucleic Acids Res 47, D1038-d1043 (2019). 13. Amberger, J.S., Bocchini, J.S., Bocchini, C.A., Scott, A.C., Bocchini, C.A., Scott, A.
13. Amberger, Hughes, T., et al. A review on the motivations, decision-making factors, attitudes and experiences of
- phenotype-gene relationships. *Nucleic Acids Res* 47, D1038-d1043 (2019).
Hughes, T., *et al.* A review on the motivations, decision-making factors, a
couples using pre-implantation genetic testing for inherited conditions 14. Hughes, T., *et al.* A review on the motivations, decision-making factors, attitudes and experiences of couples using pre-implantation genetic testing for inherited conditions. *Hum Reprod Update* 27, 944-
15. Handysid couples using pre-implantation genetic testing for inherited conditions. *Hum Reprod Opdate 27, 944-*
966 (2021).
Handyside, A.H., Pattinson, J.K., Penketh, R.J., Delhanty, J.D., Winston, R.M. & Tuddenham, E.G. Biopsy
- nandyside,
1666 (2011)
1666 (2011)
- of human preimplantation embryos and sexing by DNA amplification. *Lancet* 1, 347-349 (1989).
16. Handyside, A.H., Kontogianni, E.H., Hardy, K. & Winston, R.M. Pregnancies from biopsied human of human preimplantation embryos and sexing by DNA amplification. Lancet 1, 347-349 (1989).
Handyside, A.H., Kontogianni, E.H., Hardy, K. & Winston, R.M. Pregnancies from biopsied
preimplantation embryos sexed by Y-specifi
- preimplantation embryos sexed by Y-specific DNA amplification. Nature **344**, 768-770 (1990).
17. Proche, K., Racowsky, C. & Harper, J. Utilization of preimplantation genetic testing in the USA. J Assist premiplantation embryos sexed by Y-specific DNA amplification: Nature 344, 768-770 (1990).
Roche, K., Racowsky, C. & Harper, J. Utilization of preimplantation genetic testing in the USA
Reprod Genet 38, 1045-1053 (2021). 17. Roche, K., Racowsky, C. & Harper, J. Utilization of preimplantation genetic testing in the USA. J Assist
Reprod Genet 38, 1045-1053 (2021).
18. Spinella, F., et al. ESHRE PGT Consortium data collection XXI: PGT analyse
- Reprod Genet **38**, 1045-1053 (2021).
Spinella, F.*, et al.* ESHRE PGT Consort
2023, hoad010 (2023). 18. Spinella, F., et al. ESHRE PGT Consortium data collection XXI: PGT analyses in 2018. Hum Reprod Open
2023, hoad010 (2023). van Montfoort, A., *et al.* ESHRE PGT Consortium data collection XIX-XX: PGT analyses from 20
- 2023, hoad010 (2023).
van Montfoort, A., et .
2017. Hum Reprod Ope 19. van Montfoort, A., et al. ESHRE PGT Consortium data collection XIX-XX: PGT analyses from 2016 to
2017. Hum Reprod Open 2021, hoab024 (2021).
20. Bai, F., *et al.* Assisted reproductive technology service availability,
- 2017. Hum Reprod Open 2021, Hoaboz4 (2021).
Bai, F., *et al.* Assisted reproductive technology
China: 2016. *Hum Reprod* 35, 446-452 (2020). 20. Bai, F., et al. Assisted reproductive technology service availability, efficacy and safety in mainland
China: 2016. Hum Reprod 35, 446-452 (2020).
21. Gleicher, N., Barad, D.H., Patrizio, P. & Orvieto, R. We have reach
- China: 2016. *Hum Reprod 35, 446-452 (2020).*
Gleicher, N., Barad, D.H., Patrizio, P. & Orviet
genetic testing for aneuploidy. *Hum Reprod* 37
- genetic testing for aneuploidy. *Hum Reprod* **37**, 2730-2734 (2022).
22. Simopoulou, M., *et al.* PGT-A: who and when? A systematic review and network meta-analysis of RCTs. genetic testing for aneuploidy. *Hum Reprod 31, 2730-2734 (2022).*
Simopoulou, M., *et al.* PGT-A: who and when? A systematic review
J Assist Reprod Genet **38**, 1939-1957 (2021). 22. Simopoulou, M., et al. PGT-A: who and when? A systematic review and network meta-analysis of RCTs.
33. Munné, S., et al. Preimplantation genetic testing for aneuploidy versus morphology as selection
- J Assist Reprod Genet 38, 1939-1997 (2021).
Munné, S., et al. Preimplantation genetic
criteria for single frozen-thawed embryo 23. Munné, S., *et al.* Preimplantation genetic testing for aneuploidy versus morphology as selection criteria for single frozen-thawed embryo transfer in good-prognosis patients: a multicenter randomized clinical trial. F
- randomized clinical trial. *Fertil Steril* 112, 1071-1079.e1077 (2019).
Yan, J.*, et al*. Live Birth with or without Preimplantation Genetic Testing for Aneuploidy. *N Engl J Med* randomized clinical trial. Fertil Steril 112, 1071-1079.e1077 (2019).
Yan, J., *et al.* Live Birth with or without Preimplantation Genetic Te
385, 2047-2058 (2021). 24. Yan, J., et al. Live Birth with or without Preimplantation Genetic Testing for Aneuploidy. N Engl J Med
385, 2047-2058 (2021).
25. Mastenbroek, S., de Wert, G. & Adashi, E.Y. The Imperative of Responsible Innovation in
- 385, 2047-2058 (2021).
Mastenbroek, S., de We
Medicine. *N Engl J Med* 25. Mastenbroek, S., de Wert, G. & Adashi, E.Y. The Imperation in Redicine N Engl J Med 385, 2096-2100 (2021). M edicine. N Engl J Med 385, 2006-2100 (2021).

-
- 26. Green, Blastocysts. New England Journal of Medicine 373, 2089-2090 (2015).
27. Viotti, M., *et al.* Chromosomal, gestational, and neonatal ou Blastocysts. New England Journal by Medicine 373, 2089-2090 (2019).
Viotti, M., *et al.* Chromosomal, gestational, and neonatal outcomes c
by preimplantation genetic testing for aneuploidy. *Fertil Steril* (2023). 27. Viotti, M., *et al*. Chromosomal, gestational, and neonatal outcomes of embryos classified as a mosaic
by preimplantation genetic testing for aneuploidy. *Fertil Steril* (2023).
28. Viotti, M. Preimplantation Genetic T
- and Structural Rearrangements. Genes (Basel) 11, 602 (2020).
- 28. Viote, M. Premplantation Genetic Testing for Chromosomal Abnormalities: Aneuploidy, Mosaicism,
28. Mandyside, A.H., *et al.* Karyomapping: a universal method for genome wide analysis of genetic disease and Structural Rearrangements. Genes (Busel) 11, 602 (2020).
Handyside, A.H., *et al.* Karyomapping: a universal method for
based on mapping crossovers between parental haplotypes. J 29. Handyside, A.H., et al. Karyomapping: a universal method for genome wide analysis of genetic disease
based on mapping crossovers between parental haplotypes. *J Med Genet* 47, 651-658 (2010).
30. Zamani Esteki, M., *et*
- based on mapping crossovers between parental haplotypes. J Med Genet 47, 651-658 (2010).
Zamani Esteki, M., *et al.* Concurrent whole-genome haplotyping and copy-number profiling cells. Am. J. Hum. Genet. 96, 894–912 (2015 30. Zamani Esteki, M., et al. Concurrent whole-genome haplotyping and copy-number profiling of single-
cells. Am. J. Hum. Genet. 96, 894–912 (2015).
31. Masset, H., *et al.* Multi-centre evaluation of a comprehensive preim
- cells. Am. J. Hum. Genet. 30, 894–912 (2015).
Masset, H., *et al.* Multi-centre evaluation of
haplotyping-by-sequencing. Human Reproduc 31. Masset, H., et al. Multi-centre evaluation of a comprehensive preimplantation genetic test through
haplotyping-by-sequencing. Human Reproduction 34, 1608-1619 (2019).
32. Masset, H., et al. Single-cell genome-wide conc
- haplotyping-by-sequencing. Human Reproduction 34, 1666-1619 (2019).
Masset, H., *et al.* Single-cell genome-wide concurrent haplotyping and c
genotyping-by-sequencing. Nucleic Acids Res 50, e63 (2022). 32. Masset, H., et al. Single-cell genome-wide-concurrent haplotyping and copy-number profilms through-
genotyping-by-sequencing. Nucleic Acids Res 50, e63 (2022).
33. Backenroth, D., *et al.* Haploseek: a 24-hour all-in-o
- genotyping-by-sequenting. Nucleic Acids Res 30, e63 (2022).
Backenroth, D., *et al.* Haploseek: a 24-hour all-in-one meth
(PGD) of monogenic disease and aneuploidy. *Genet Med* 21, 33. Backerhoth, D., et al. Haploseek: a 24-hour all-in-one method for premiplantation genetic diagnosis
(PGD) of monogenic disease and aneuploidy. *Genet Med* 21, 1390-1399 (2019).
34. Zeevi, D.A., *et al.* Expanded clinic
- (PGD) of monogenic disease and aneuploidy. Genet Med 21, 1390-1399 (2019).
Zeevi, D.A., *et al.* Expanded clinical validation of Haploseek for comprehensive p
testing. *Genet Med* 23, 1334-1340 (2021). 34. Zeevi, D.A., *et al.* Expanded clinical validation of Haploseek for comprehensive preimplantation genetic
135. testing. *Genet Med* 23, 1334-1340 (2021).
135. Backenroth, D., *et al.* SHaploseek: A sequencing-only high
- comprehensive preimplantation genetic testing. medRxiv, 2023.2006.2006.23291016 (2023). $\frac{35.}{25.}$ Backenroth, D., et al. Shaploseck: A sequencing-only high-resolution implementation of
comprehensive preimplantation genetic testing. $medRxiv$, 2023.2006.2006.23291016 (2023).
36. De Witte, L., *et al.* GENType
- comprehensive preimplantation genetic testing. *mediatic, 2023.2006.2006.23291016* (2023).
De Witte, L., *et al.* GENType: all-in-one preimplantation genetic testing by pedigree haploty
copy number profiling suitable for t 36. De Witte, L., et al. GENType: all-in-one premiplantation genetic testing by pedigree haplotyping and
copy number profiling suitable for third-party reproduction. Hum Reprod 37, 1678-1691 (2022).
37. Griffin, D.K. & Ogu
- copy number profiling suitable for third-party reproduction. *Hum Reprod 37, 1678-1691 (2022).*
Griffin, D.K. & Ogur, C. PGT-SR: A Comprehensive Overview and a Requiem for the Interchrome
Effect. DNA 3, 41-64 (2023). 37. Griffin, D.K. & Ogur, C. PGT-SR: A Comprehensive Overview and a Requiem for the Interchromosomal
Effect. DNA 3, 41-64 (2023).
38. Gui, B., *et al.* Chromosomal analysis of blastocysts from balanced chromosomal rearrang
- carriers. Reproduction 151, 455-464 (2016). 38. Gui, B., et al. Chromosomal analysis of blastocysts from balanced chromosomal rearrangement
carriers. Reproduction 151, 455-464 (2016).
39. Sallevelt, S.C., et al. Preimplantation genetic diagnosis in mitochondrial DNA
- carriers. Reproduction 151, 455-464 (2016).
Sallevelt, S.C., *et al.* Preimplantation genetics 39. Sallevelt, S.C., *et al.* Preimplantation genetic diagnosis in mitochondrial DNA disorders: challenge and
success. *J Med Genet* 50, 125-132 (2013).
40. Haenel, Q., Laurentino, T.G., Roesti, M. & Berner, D. Meta-analys
- success. *J Med Genet 50, 125-132 (2013).*
Haenel, Q., Laurentino, T.G., Roesti, M.
rate variation in eukaryotes and its signific 40. Hammer, Q., Laurentino, T.G., Haren, M. G. Berner, B. Meta-analysis of chromosome-scale crossover
rate variation in eukaryotes and its significance to evolutionary genomics. Molecular Ecology 27, 2477-
2497 (2018). rate variation in eukaryotes and its significance to evolutionary genomics. Molecular Ecology 27, 2477-
2497 (2018).
Viotti, M. Preimplantation Genetic Testing for Chromosomal Abnormalities: Aneuploidy, Mosaicism,
- ر
2014 (Viotti, M. Pre
2014 Structura
- and Structural Rearrangements. *Genes (Basel)* 11(2020).
42. Xu, J., *et al.* Mapping allele with resolved carrier status of Robertsonian and reciprocal translocation in and Structural Rearrangements. Genes (Basel) 11(2020).
Xu, J., *et al.* Mapping allele with resolved carrier status of human preimplantation embryos. *Proc Natl Acad Sci U S* 42. Xu, J., *et al.* Mapping allele with resolved carrier status of Robertsonian and reciprocal translocation in
human preimplantation embryos. *Proc Natl Acad Sci U S A* 114, E8695-e8702 (2017).
43. Zhai, F., *et al.* Pre
- human preimplantation embryos. Proc Natl Actu Scr 0 3 A 114, E8695-e8702 (2017).
Zhai, F., *et al.* Preimplantation genetic testing for structural rearrangement based
next-generation sequencing accurately discriminates bet 43. Zhai, F., et al. Premiplantation genetic testing for structural rearrangement based on low-coverage
next-generation sequencing accurately discriminates between normal and carrier embryos for patients
with translocation with translocations. Reprod Biomed Online 45, 473-480 (2022).
Xia, Q., et al. Nanopore sequencing for detecting reciprocal translocation carrier status in
- preimplantation genetic testing. BMC Genomics 24, 1 (2023). 44. Xia, Q., et al. Nanopore sequencing for detecting reciprocal translocation carrier status in
preimplantation genetic testing. BMC Genomics 24, 1 (2023).
45. Xia, Y., *et al.* Validation of the first PGT-whole genome se
- premiplantation genetic testing. BMC Genomics 24, 1 (2023).
Xia, Y., *et al.* Validation of the first PGT-whole genome sequ
variants. *bioRxiv*, 2022.2004.2014.488421 (2022). 45. Xia, *P., et al. Validation of the first PGT-whole genome sequencing approach including mitochondrial*
variants. *bioRxiv*, 2022.2004.2014.488421 (2022).
46. Xia, Y., *et al.* Genome-Wide Disease Screening in Early Hum
- variants. *bionalv, 2022.2004.2014.488421 (2022).*
Xia, Y., *et al.* Genome-Wide Disease Screening
Directed Amplification. *bioRxiv,* 2021.2007.2006.4 46. Xia, Y., *et al.* Genome-Wide Disease Screening in Early Human Embryos with Primary Template-
Directed Amplification. *bioRxiv*, 2021.2007.2006.451077 (2021).
47. van Prooyen Schuurman, L., *et al.* Clinical impact of
- Directed Amplification. *biotism, 2021.2007.2000.451077 (2021).*
Van Prooyen Schuurman, L., *et al.* Clinical impact of additional fii
invasive prenatal testing: Follow-up results of the TRIDENT-2 sti 47. van Frooyen Schuurman, L., et al. Clinical impact of duditional midnigs detected by genome-wide non-
invasive prenatal testing: Follow-up results of the TRIDENT-2 study. Am J Hum Genet 109, 1140-1152
(2022). (2022).
Sachdev, N.M., McCulloh, D.H., Kramer, Y., Keefe, D. & Grifo, J.A. The reproducibility of trophectoderm
- 、_____,
Sachde
biopsie: 48. Sachdev, N.M., McCulloh, N.M., Sachdev, N.M., Sachdev, N.M., Sachdev, N.M., Sachdev, N.M., Shopsies in euploid, aneuploid, and mosaic embryos using independently verified next-generation
sequencing (NGS): a pilot study
- sequencing (NGS): a pilot study. *J Assist Reprod Genet* 37, 559-571 (2020).
Orvieto, R. The reproducibility of trophectoderm biopsies The chaos behind preimplantation genetic testing for aneuploidy. Eur J Obstet Gynecol Reprod Biol 254, 57-58 (2020). testing for aneuploidy. *Eur J Obstet Gynecol Reprod Biol* 254, 57-58 (2020).
50. Victor, A.R.*, et al.* Assessment of aneuploidy concordance between clinical trophectoderm biopsy and
- testing for aneuploidy. *Eur J Obstet Gynecol Reprod Biol 254, 57-58* (2020).
Victor, A.R., *et al.* Assessment of aneuploidy concordance between clinical
blastocyst. Hum Reprod 34, 181-192 (2019). 50. Victor, A.R., et al. Assessment of aneuploidy concordance between clinical trophectoderm biopsy and
51. Gleicher, N., Patrizio, P., Mochizuki, L. & Barad, D.H. Previously reported and here added cases
- blastocyst. Hum Reprod 34, 101-152 (2015).
Gleicher, N., Patrizio, P., Mochizuki, L. &
demonstrate euploid pregnancies followed 51. Gleicher, N., Patrizio, P., Mochizuki, L. & Barad, D.H. Previously reported and here added cases
demonstrate euploid pregnancies followed by PGT-A as "mosaic" as well as "aneuploid" designated embryos. Reproductive Biology and Endocrinology **21**, 25 (2023). embryos. Reproductive Biology and Endocrinology 21, 25 (2023).
- 52. Yang, M., et al. Depletion of aneuploid cells in human embryos and gastruloids. Nature Cell Biology 23,
314-321 (2021).
53. Rana, B., *et al.* Identifying parental and cell-division origins of aneuploidy in the human b
- 221122, 2022, 2021
Rana, B., *et al.* 10
J Hum Genet **110** 53. Rana, B., et al. Identifying parental and cell-division origins of aneuploidy in the human blastocyst. Am
- testing in a national screening program. Eur J Hum Genet 31, 555-561 (2023). 54. van der Meij, K.R.M., et al. Experiences of pregnant women with genome-wide non-invasive prenatal-
testing in a national screening program. *Eur J Hum Genet* 31, 555-561 (2023).
55. Souche, E., *et al.* Recommendations
- testing in a national screening program. *Eur J Hum Genet 31, 555-561* (2023).
Souche, E., *et al.* Recommendations for whole genome sequencing in diagi
European Journal of Human Genetics **30**, 1017-1021 (2022). 55. Souche, E., et al. Recommendations for whole genome sequencing in diagnostics for rare diseases.
European Journal of Human Genetics 30, 1017-1021 (2022).
56. Kothiyal, P., Wong, W.S.W., Bodian, D.L. & Niederhuber, J.E.
- European Journal of Human Genetics 30, 1017-1021 (2022).
Kothiyal, P., Wong, W.S.W., Bodian, D.L. & Niederhuber, J.I
1314 Ancestrally Diverse Family Trios Distinguish Biological 56. Kothiyal, P., Wong, W.S.W., Bodian, D.L. & Niederhuber, J.E. Mendelian Inconsistent Signatures from
1314 Ancestrally Diverse Family Trios Distinguish Biological Variation from Sequencing Error. *J Comput*
157. Kong, A. 1314 Ancestrally Biverse Family Trios Bistinguish Biological Variation from Sequencing Error. J computerion and the
Biol 26, 405-419 (2019).
Kong, A., *et al.* Rate of de novo mutations and the importance of father's age t
- Biol 20, 405-419 (2019).
Kong, A., *et al.* Rate of c
488, 471-475 (2012). **488**, 471-475 (2012).
58. Shamonki, M.I., Jin, H., Haimowitz, Z. & Liu, L. Proof of concept: preimplantation genetic screening
- 488, 471-475 (2012).
Shamonki, M.I., Jin, I
without embryo biop without embryo biopsy through analysis of cell-free DNA in spent embryo culture media. Fertil Steril
106, 1312-1318 (2016). without embryo biopsy through analysis of cell-free DNA in spent embryo culture media. Fertil Steril
106, 1312-1318 (2016).
Rubio, C., *et al.* Multicenter prospective study of concordance between embryonic cell-free DNA a
- 100, 1312-1310 (2010).
Rubio, C., *et al*. Multice
trophectoderm biopsies 59. Rubio, C., *et al.* Multicenter prospective study of concordance between embryonic cell-free DNA and
1301 human blastocysts. Am J Obstet Gynecol 223, 751.e751-751.e713
2020). Chen, Y., *et al.* DNA methylome reveals ce trophectoderm biopsies from 1301 human blastocysts. Am J Obstet Gynecol 223, 751.e751-751.e713
(2020).
Chen, Y., *et al.* DNA methylome reveals cellular origin of cell-free DNA in spent medium of human
- 、
Chen, Y
preimpl 60. Chen, Y., et al. DNA methylome reveals cellular origin of cell-free DNA in spent medium of human
preimplantation embryos. The Journal of Clinical Investigation 131(2021).
61. Zamani Esteki, M., *et al.* In vitro fertil
- premiplantation embryos. The Journal of Clinical Investigation 131(2021).
Zamani Esteki, M., *et al.* In vitro fertilization does not increase the incide
alterations in fetal and placental lineages. Nature Medicine 25, 169 61. Zamani Esteki, M., et al. In vitro fertilization does not increase the including of de novo copy number
alterations in fetal and placental lineages. *Nature Medicine* 25, 1699-1705 (2019). alterations in fetal and placental lineages. Nature Medicine 25, 1699-1705 (2019).

Figure legends

Fig. 1: Overview study workflow and key parameters. a, The study's workflow including embryo biopsy, DNA amplification, library preparation (GBS and WGS), sequencing, analysis, and clinical diagnosis. **b,** study sample in diagnosis. **b,** study sample inclusion diagram. **c,** library preparation times in hours for GBS and WGS methods. Black outline represents hands-on time per step. **d**, boxplot showing the breadth of coverage for subsampled diagnosis. **b,** study sample inclusion diagram. **c**, morary preparation times in hours for GBS and WGS methods. Black outline represents hands-on time per step. **d**, boxplot showing the breadth of coverage for subsampled W methods. Black outline represents hands on time per step. **a**, boxplot showing the breadth of
coverage for subsampled WGS samples $(n = 12 \text{ per target coverage})$ compared to corresponding GBS
samples and for 10X WGS samples $(n = 84)$. **e**, coverage for subsamples for coverage (n = 12 per target coverage) compared to corresponding depth
samples and for 10X WGS samples (n = 84). **e**, half violin plot, overlayed with boxplot showing depth
of coverage for WGAed samples and for 10X WGS samples (n = 64). c , half violin plot, overlayed with boxplot showing depth of coverage for WGAed embryo and bulk gDNA samples for GBS and WGS. Each dot represents an individual sample. **f**, Mend individual sample. **f**, Mendelian inconsistency rate for 10X embryo samples (*n* = 31 per method). **G**, genome-wide haplotype concordance of WGS with GBS indicated per parent (maternal, *n* = 23; paternal, *n* = 25). In a maryidual sample. **i**, Mendelian inconsistency rate for 10X embryo samples (n = 31 per method). **c,**
genome-wide haplotype concordance of WGS with GBS indicated per parent (maternal, n = 23;
paternal, n = 25). In all boxp paternal, $n = 25$). In all boxplots the horizontal lines of the boxplot represent the 25^{th} percentile, median and 75th percentile. The whiskers extend to $1.5 * IQR$.
GBS: genotyping-by-sequencing; WGS: whole genome seq

paternal, *n* = 25). In all boxplots the horizontal lines of the boxplot represent the 25th percentile,
median and 75th percentile. The whiskers extend to 1.5 * IQR.
GBS: genotyping-by-sequencing; WGS: whole genome seq median and 75^{cm} percentile. The whiskers extend to 1.5 * IQR.
GBS: genotyping-by-sequencing; WGS: whole genome sequer
whole genome amplified.
Fi**g. 2: PGT for monogenic disorders. a,** Representative haplari

GBS: genome amplified.
Whole genome amplified.
Fig. 2: PGT for monogenic disorders. a, Representative haplarithms for all types of PGT-M indications,
i.e. AD (family 10), AR (family 6), X-R (family 7), and highlighting the whole genome amplified.
Fig. 2: PGT for monogenic
i.e. AD (family 10), AR (fan
compared to GBS-PGT. Th rig. 2: PGT for monogenic disorders. a, Representative haplarithms for all types of PGT-M indications,
i.e. AD (family 10), AR (family 6), X-R (family 7), and highlighting the increased resolution of WGS-PGT
compared to GB compared to GBS-PGT. The top panel shows family pedigrees. The lower panel shows haplarithms
generated with GBS (gold) and WGS (blue) – from top to bottom – BAF profiles, interpreted paternal
haplotypes (paternal H1: darkb generated with GBS (gold) and WGS (blue) – from top to bottom – BAF profiles, interpreted paternal
haplotypes (paternal H1: darkblue; paternal H2: lightblue), Pat-BAFs, interpreted maternal haplotypes
(maternal H1: red; ma haplotypes (paternal H1: darkblue; paternal H2: lightblue), Pat-BAFs, interpreted maternal haplotypes
(maternal H1: red; maternal H2: pink), Mat-BAFs, logR values representing the log2 ratio of the
observed copy numbers to maternal H1: red; maternal H2: pink), Mat-BAFs, logR values representing the log2 ratio of the observed copy numbers to the expected copy number. The ROI is indicated by an orange line. **b**, Genotypes ascertained by direct (materia) observed copy numbers to the expected copy number. The ROI is indicated by an orange line. **b,** Genotypes ascertained by direct mutation detection (obs) compared to the haplarithmisis result (exp) subdivided for Observed copy numbers to the expected copy number. The ROI is indicated by an orange line. **b,**
Genotypes ascertained by direct mutation detection (obs) compared to the haplarithmisis result (exp)
subdivided for genetic in subdivided for genetic indications that included SNVs or single nucleotide deletions. Embryos are
numbered, and the indications are indicated in superscript (1: indication 1, 2: indication 2, a or b
indicate different gene subdivided for general minimization and interact of the stringle indication 1, 2: indication 2, a or b
indicate different genetic loci in case of a compound heterozygous mutation). The mutant allele track
shows the type of indicate different genetic loci in case of a compound heterozygous mutation). The mutant allele track
shows the type of inheritance indicated by AR or AD, and the triangle is coloured with the mutant
allele (A = green, C shows the type of inheritance indicated by AR or AD, and the triangle is coloured with the mutant allele (A = green, C = orange, G = blue, T = red, del = grey). The concordance of diagnosis and genotype with the haplarith shows the type of inheritance indicated by AR or AD, and the triangle is concordance of diagnosis and genotype with the haplarithmisis result is colour-coded (concordant = green, not concordant = red, inconclusive = orang genotype with the haplarithmisis result is colour-coded (concordant = green, not concordant = red,
inconclusive = orange). Recessive indications were considered inconclusive if the proportion of reads
supporting the refer genotype with the happentumine extended to the result (concordant = green, not concretant = red,
inconclusive = orange). Recessive indications were considered inconclusive if the proportion of reads
supporting the referenc

supporting the reference allele were <30% or >60%.
PGT: preimplantation genetic testing; M: monogenic; AR: autosomal recessive; AD: autosomal
dominant; X-R: X-linked recessive; BAF: B-allele frequency; Pat: paternal; Mat: supporting the reference allele were <50% or >60%.
PGT: preimplantation genetic testing; M: monogedominant; X-R: X-linked recessive; BAF: B-allele freq
of interest; GBS: genotyping-by-sequencing; WGS:
observed; del: deleti PET: premplantation general terms) in intensigning the autocrimal recessive, the cancel and
dominant; X-R: X-linked recessive; BAF: B-allele frequency; Pat: paternal; Mat: maternal; ROI: region
of interest; GBS: genotyping of interest; GBS: genotyping-by-sequencing; WGS: whole genome sequencing; exp: expected, obs:
observed; del: deletion. observed; del: deletion.
observed; del: deletion. observed; del: deletion.

ا
)
) Fig. 3. PGT for aneuploidy origin. a, Schemate representation or trisomics with different segregational origins (meiosis I, meiosis II or mitotic trisomy) are shown, using close-relative phasing
or using parents-only phasi segregational origin. The segregational origin using parents-
only phasing was determined by inspecting the distance between the segmented P1/M1 and P2/M2
at the centromeric and telomeric region. Further explanation is pro was determined by calculating the distance between paternal and maternal BAF segments as only phasing the determined by the pering the distance between in the eigenstick explorementary Note. **b**, Representative cases of aneuploidies with different degrees of mosaicism. The degree of mosaicism was determined by at the echtromeric and telomeric region. Further explanation is provided in Supplementary Note. b,
Representative cases of aneuploidies with different degrees of mosaicism. The degree of mosaicism
was determined by calcula Representative cases of an experiment most extend and material in the degree of most
andicated with curly brackets. **c**, Representative haplarithms of embryos with trisomies with a
different segregational origins. Top pane indicated with curly brackets. **c,** Representative haplarithms of embryos with trisomies with a
different segregational origins. Top panel: schematic of the chromosomal constitution. Middle panel:
haplarithms when using a indicated with curry blackets. C, Representative haplantims of embryos with trisomies with a
different segregational origins. Top panel: schematic of the chromosomal constitution. Middle panel:
haplarithms when using a clo haplarithms when using a close relative as referent. Bottom panel: haplarithms when using the same
embryo as referent to phase the parents and define the segregational origin. Curly brackets indicate
the distance between t embryo as referent to phase the parents and define the segregational origin. Curly brackets indicate
the distance between the paternal and maternal BAF segments.
Fig. 4. PGT for structural rearrangements. Representative ha

embryo as referent to phase the parents and activity and define the distance between the paternal and maternal BAF segments.
Fig. 4. PGT for structural rearrangements. Representative haplarithms for embryos with structural Fig. 4. PGT for structural rearrangements. Representative hap
rearrangements. Two embryos from family 1 are shown where
translocation between chr8 and chr16 as indicated by the sch |
|
|
| Fig. 4. POT for structural rearrangements. Representative haplarminis for embryos with structural
rearrangements. Two embryos from family 1 are shown where the structural rearrangement is a
translocation between chr8 and c reanslocation between chr8 and chr16 as indicated by the schematic chromosome representation.
Haplarithms include BAFs, paternal haplotypes, Pat-BAF and copy number indicated by logR with
breakpoints as identified by Manta translation between chream chris and christian applies throughout the suppresentation.
Haplarithms include BAFs, paternal haplotypes, Pat-BAF and copy number indicated by logR with
breakpoints as identified by Manta (green Breakpoints as identified by Manta (green) and flanking haplotypes H1 (darkblue) and H2 (lightblue)
indicated by the dashed box.
PGT: preimplantation genetic testing; BAFs: B-allele frequencies; Pat: paternal; H1: haplotyp

be a the model of the dashed box.

PGT: preimplantation genetic testing; BAFs: B-allele frequencies; Pat: paternal; H1: haplotype 1; H2:

haplotype 2.

Fig. 5. PGT for mtDNA diagrams A. Urbanglangy layer layer is an 2343A. indicate of the dashed by PGT: preimplantation genetic
haplotype 2.
Fig. 5. PGT for mtDNA disor

Premiplantation generalizang; BAFs: B-allele Frequencies; Paternal; H2: haplotype 2; B-allele frequencies; R5: Paternal; Barsel and Barse Fig. 5. PGT free PCR-RFLP for
PCR-RFLP for
or using ~10) |
|
|
| FIG. 5. PGT for musical disorders. a, Heteroplasmy levels in m.5243A>G embryos as determined by
PCR-RFLP for day-3 blastomere biopsy, day-5 TE biopsy and surplus embryo material (embryos 41-44)
or using ~10X WGS-PGT (embr Framer Framer for m and surplus and surplus emprise that y is interesting (embryon in shown
for ~10X WGS-PGT data from embryos sequenced for PGT-M or PGT-SR (outer ring, $n = 23$), deep
sequencing with subsequent sub-s for ~10X WGS-PGT data from embryos 45-50). **b**, Mean depth of coverage per mtDNA position is shown
for ~10X WGS-PGT data from embryos sequenced for PGT-M or PGT-SR (outer ring, $n = 23$), deep
sequencing with subsequent su sequencing with subsequent sub-sampling for PGT-MT (middle ring, $n = 4$) and direct ~10X sequencing for PGT-MT (inner ring, $n = 2$). Position 0 is at the top with the positions ordered clockwise and colour representing th sequencing for PGT-MT (inner ring, $n = 2$). Position 0 is at the top with the positions ordered clockwise and colour representing the number of reads per position. The MELAS mutation position (m.3243) is highlighted as a sequencing for PGT-MT (inner ring) in Eq. 1 sends to the top with the position constituted
clockwise and colour representing the number of reads per position. The MELAS mutation position
(m.3243) is highlighted as a separa

(m.3243) is highlighted as a separate segment and magnified 30x compared to all other positions.
PGT: preimplantation genetic testing; MT: mitochondrial DNA disorders; RFLP: restriction fragment
length polymorphism; TE: tr (m.3243) is highlighted as a separate segment and magnified 30x compared to all other positions.
PGT: preimplantation genetic testing; MT: mitochondrial DNA disorders; RFLP: restriction fragm
length polymorphism; TE: troph length polymorphism; TE: trophectoderm biopsy; WGS: whole genome sequencing; M: monogenic; SR: structural rearrangement; mtDNA: mitochondrial DNA. SR: structural rearrangement; mtDNA: mitochondrial DNA. SR: structural rearrangement; mtDNA: mitochondrial DNA.

Fig. 6. WGS-PGT as an all-in-one method. Illustrations and characteristics of PGT methods. WGS-PGT
serves as an all-in-one method that captures all the functions within a single approach, while more
traditional PGT methods serves are traditional PGT methods are each designed for a specific purpose.
WGS: whole genome sequencing; PGT: preimplantation genetic testing
with a single more more more more more more testing. traditional PGT methods are each designed for a specific purpose.
WGS: whole genome sequencing; PGT: preim

WGS: whole genome sequencing; PGT: preimplantation genetic testing.

Study participants and ethical approval

**Study par
Couples w
Couples w
and enrol**
Ministry Couples were counseled by clinical geneticists at Maastricht University Medical Centre + (MUMC+)
and enrolled in the diagnostic preimplantation genetic testing (PGT) procedure (licensed by the Dutch
Ministry of Health, Wel methods. Full ethics committee approval was not required owing to the retrospective design of the
study and the anonymized handling of the data under file number 2023-0091 from the ethics Ministry of Health, Meaning and Sport C2-TC2-2022, and Spaing an informed consent of PGT
Couples who underwent PGT, consented for the use of affected embryos for the development of PGT
methods. Full ethics committee approv Couples who undertained for the use of affected embryos for the userspective design of the
study and the anonymized handling of the data under file number 2023-0091 from the ethics
committee from the Maastricht UMC+. Genet methods. Full ethics committed approval was not required entity of the retrospective design of the
study and the anonymized handling of the data under file number 2023-0091 from the ethics
committee from the Maastricht UMC studies the Manustricht UMC+. Genetic and clinical data shared in the context in this study
cannot be used to identify individuals. We included 21 families who had undergone PGT for (double)
monogenic, structural, or mitoc cannot be used to identify individuals. We included 21 families who had undergone PGT for (double)
monogenic, structural, or mitochondrial indications where spare (amplified) DNA from all samples
was available. No addition cannoting the used to identify individuals in the interaction 21 community interacting to its (double)
monogenic, structural, or mitochondrial indications where spare (amplified) DNA from all samples
was available. No addi was available. No additional biopsies were performed for this study specifically, except for PGT-MT
(see in section PGT for mitochondrial DNA disorders). was available the additional biopsies were performed for this study operation, enough for this interference
(see in section PGT for mitochondrial DNA disorders).
GBS-PGT-M the standard clinical procedure in our facility in

GBS-PGT sample collection and processing

(see in the section of the Ses-PGT sample collection and processing
For PGT-M the standard clinical procedure in our facili
described previously⁶². These procedures are part (
|
|} described previously⁶². These procedures are part of standard clinical practice and were not
performed for this study specifically. Briefly, peripheral blood samples were collected from
prospective parents and close rel performed for this study specifically. Briefly, peripheral blood samples were collected from
prospective parents and close relatives from which DNA was isolated using the QIAsymphony DSP
DNA Midi kit (Qiagen, Germany). A t prospective parents and close relatives from which DNA was isolated using the QIAsymphony DSP
DNA Midi kit (Qiagen, Germany). A trophectoderm (TE) biopsy, *i.e.* 5-10 cells, was taken from
sufficiently developed embryos on provide in the collected material was subjected to multiple
providently developed embryos on day-5 and the collected material was subjected to multiple
displacement amplification (MDA) using the REPLI-g Single Cell kit (Qi Bufficiently developed embryos on day-5 and the collected material was subjected to multiple
displacement amplification (MDA) using the REPLI-g Single Cell kit (Qiagen, Germany), following the
manufacturer's instructions. sufficiently developed embry of the may of the the collected material material was energy in manipological displacement amplification (MDA) using the REPLI-g Single Cell kit (Qiagen, Germany), following the manufacturer's manufacturer's instructions. Library preparation, using the OnePGT solution (Agilent Technologies)
was then carried out on genomic DNA samples from parents and close relative(s), along with the
whole genome amplified (WGAe was then carried out on genomic DNA samples from parents and close relative(s), along with the
whole genome amplified (WGAed) samples from embryos, following the manufacturer's instructions
and as previously described⁶². whole genome amplified (WGAed) samples from embryos, following the manufacturer's instructions
and as previously described⁶². The libraries were sequenced on a NextSeq 500 sequencing system. All
excess DNA not used for l and as previously described⁶². The libraries were sequenced on a NextSeq 500 sequencing system. All excess DNA not used for library preparation was stored at -20 \degree C, in accordance with clinical standards. excess DNA not used for library preparation was stored at -20 °C, in accordance with clinical standards.

Whole genome sequencing sample processing

DNA from parents and close relative(s) and WGAed DNA from embryos, (see above) that was stored standards
Whole gen
DNA from _|
according \
[
} according to clinical standards, was subjected to whole genome sequencing (WGS) library
preparation. Briefly, a minimum input of 20 μ l, with a concentration of 30 ng/ μ l, was supplemented
with 0.12 ng of embryo track preparation. Briefly, a minimum input of 20 μ l, with a concentration of 30 ng/ μ l, was supplemented with 0.12 ng of embryo tracking system (ETS) fragments (concentration: 0.03 ng/ μ l)⁶³. Subsequently, with 0.12 ng of embryo tracking system (ETS) fragments (concentration: 0.03 ng/ μ l)⁶³. Subsequently, with 0.12 ng of embryo tracking system (ETS) fragments (concentration: 0.03 ng/ μ l)⁶³. Subsequently,
,
,

bead-linked transposome (BLT) PCR-free library preparation (Illumina, San Diego) was carried out according to the manufacturer's instructions for input quantities ranging from 300 to 2000 ng. The resulting libraries were p resulting libraries were purified using a double-sided bead purification process. Sequencing was performed using a NovaSeq 6000 in the Radboudumc to a target depth of coverage of ~30X-40X or

Sequencing data processing and quality control

The raw sequencing data were demultiplexed and aligned to the human reference genome - - - -
Sequ
The
(com $\frac{3}{2}$ (complemented with the sequences of all ETS amplicons) using bwa-mem2 (v. 2.2.1)⁶⁴. The WGS data were aligned to hg38 while the GBS data were aligned to hg37, and positions were then converted to hg38 using liftOver fro (complemented with the sequences of all ETS amplicons) using bwa-mem2 (v. 2.2.1)⁶⁴. The WGS data
were aligned to hg38 while the GBS data were aligned to hg37, and positions were then converted to
hg38 using liftOver from were angular to hgas data were aligned to hgas parallel the GBS data were aligned to have a
hg38 using liftOver from the Rtracklayer package⁶⁵. The quality of the resulting alignment was
assessed using Qualimap (v.2.2.1. hg38 using liftOver from the Rtracklayer package⁹⁹. The quality of the resulting alignment was
assessed using Qualimap (v.2.2.1.)⁶⁶ to determine breadth and depth of coverage as well as the purity
of the expected ETS f

assessed using Qualimap (v.2.2.1.)⁹⁶ to determine breadth and depth of coverage as well as the purity
of the expected ETS fragment.
Samples that underwent deep (~40X) sequencing, were subsampled using the "view" function Samples that underwent deep
SAMtools (v. 1.15.1)⁶⁷. The frac
calculated by dividing the targ
Rank-Sum Tests were used to SAMtools (v. 1.15.1)⁶⁷. The fraction of the original bam file required to generate different subsets was calculated by dividing the target coverage (5X, 10X, 20X and 30X) by the original coverage. Wilcoxon Rank-Sum Test SAMtools (v. 1.15.1)". The fraction of the original bam file required to generate different subsets was
calculated by dividing the target coverage (5X, 10X, 20X and 30X) by the original coverage. Wilcoxon
Rank-Sum Tests we Rank-Sum Tests were used to compare the GBS and WGS groups and Kruskal-Wallis test with Dunn's
multiple comparisons test to compare the different target coverage groups.
Haplarithmisis-based PGT

GBS and WGS data were analysed using a modified version of the siCHILD analytical pipeline that is maplarithmisis-based PGT
GBS and WGS data were analysed using a modified version of the siCHILD
equipped with haplarithmisis⁶⁸ and has been further adapted for sequ |
|
|} Hapland WGS data were a
GBS and WGS data were a
equipped with haplarithm
preparatory test was cond
was eligible for PGT. Subs equipped with haplarithmisis⁶⁸ and has been further adapted for sequencing data⁶³. Initially, a
preparatory test was conducted for the parents and close relative(s) to assess whether the couple
was eligible for PGT. Su preparatory test was conducted for the parents and close relative(s) to assess whether the couple
was eligible for PGT. Subsequently, an "embryo test" was run in which embryo haplotypes were
reconstructed to ascertain a d was eligible for PGT. Subsequently, an "embryo test" was run in which embryo haplotypes were
reconstructed to ascertain a diagnosis. Using this pipeline, aligned sequencing data was processed
using Joint HaplotypeCaller f reconstructed to ascertain a diagnosis. Using this pipeline, aligned sequencing data was processed
using Joint HaplotypeCaller from GATK (v. 3.4-46)⁶⁹ to extract the genomic locations in the dbSNP
database (v. 150). All using Joint HaplotypeCaller from GATK (v. 3.4-46)⁶⁹ to extract the genomic locations in the dbSNP
database (v. 150). All subsequent processing was carried out in R (version 3.3.1)⁷⁰ as previously
described^{63,68}. Bri using Joint HaplotypeCaller from GATK (v. 3.4-46)⁹⁵ to extract the genomic locations in the dbSNP
database (v. 150). All subsequent processing was carried out in R (version 3.3.1)⁷⁰ as previously
described^{63,68}. Brie described^{63,68}. Briefly, the GATK output was used to determine the genotype per position of each sample using vcfR (v. 1.8.0.9000)⁷¹ R package. This was used to calculate B allele frequencies (BAF), which were subsequ described^{89,68}. Briefly, the GATK output was used to determine the genotype per position of each
sample using vcfR (v. 1.8.0.9000)⁷¹ R package. This was used to calculate B allele frequencies (BAF),
which were subseque sample using vcfR (v. 1.8.0.9000)²² R package. This was used to calculate B allele frequencies (BAF),
which were subsequently phased by leveraging information from the parents and a close relative.
Segmentation of the pa Segmentation of the parent specific phased BAFs was used to determine the haplotypes. Copy
number states for 100kb-sized genomic bins were assessed using the QDNAseq (v. 1.10.0)⁷² R package
and segmented using piecewise Number states for 100kb-sized genomic bins were assessed using the QDNAseq (v. 1.10.0)⁷² R package
and segmented using piecewise constant fitting (PCF)⁷³ with a gamma value of 50. GBS-PGT requires
eight informative SN and segmented using piecewise constant fitting (PCF)⁷³ with a gamma value of 50. GBS-PGT requires eight informative SNPs at either 2Mb side of the region of interest (ROI) (Supplementary Table 2). eight informative SNPs at either 2Mb side of the region of interest (ROI) (Supplementary Table 2).

The proportion of these information on a single include the stock solid cancel and state in the state in the
affected or unaffected haplotypes as determined by parental phasing.
Haplarithmisis comparison between GBS and WG

Haplarithmisis comparison between GBS and WGS

and or the set of the set of the set of the Haplarithmisis comparison between GBS and WGS
Haplarithmisis output was evaluated from subsampled data generated
assessing mendelian inconsistency level, number of informative SN |
|
|
| Experimental enapsi was evaluated from subsampled data generated at \sim 10X depth of correctings approximations assessing mendelian inconsistency level, number of informative SNPs, and haplotype concordance.
The assessmen The assessment criteria for the preparatory test and embryo test are listed (Supplementary Table 2).
Mendelian inconsistency rate was defined as the proportion of inconsistent genotypes out of the
total number of genotypes The assessment criteria for the preparatory test and embryo test are listed (Supplementary Table 2).
Mendelian inconsistency rate was defined as the proportion of inconsistent genotypes out of the
total number of genotypes Mendel number of genotypes that were analysed. These rates were calculated for individual
chromosomes and then the mean for all autosomes was calculated. Haplotype concordance between
GBS and WGS was determined by comparin thromosomes and then the mean for all autosomes was calculated. Haplotype concordance between
GBS and WGS was determined by comparing the interpreted haplotypes per parent. Subsequently,
the haplotype concordance of WGS-PG Chromosomes and WGS was determined by comparing the interpreted haplotypes per parent. Subsequently, the haplotype concordance of WGS-PGT with GBS-PGT was assessed for each target coverage using Kruskal-Wallis test followe the haplotype concordance of WGS-PGT with GBS-PGT was assessed for each target coverage using
Kruskal-Wallis test followed by Dunn's multiple comparisons test. the happer, percent handle of WGS-PGT with GBS-PGT was assessed for each target correngements.
Kruskal-Wallis test followed by Dunn's multiple comparisons test.
Direct mutation detection
Single nucleotide variants (SNVs) a

Direct mutation detection

Direct mutation detection
Single nucleotide variants (SNVs) and deletions in affected embry
nucleotides at the base-level. We analysed genetic loci that er 【
2
「 nucleotides at the base-level. We analysed genetic loci that entailed single nucleotide alterations
such as SNVs and deletions. In total 22 genetic loci were included, of which 19 SNVs and three
deletions. Moreover, 11 gen such as SNVs and deletions. In total 22 genetic loci were included, of which 19 SNVs and three
deletions. Moreover, 11 genetic loci were analysed that entailed deletions ranging 2 bp from 398 kb.
Reads mapping the relevant deletions. Moreover, 11 genetic loci were analysed that entailed deletions ranging 2 bp from 398 kb.
Reads mapping the relevant genetic location were extracted from bam files by indicating the
chromosome, start and end pos Reads mapping the relevant genetic location were extracted from bam files by indicating the chromosome, start and end position of a genomic interval using the SAMtools "view" function⁶⁷. The resulting bam files were visu Reads mapping the relevant general term in the extracted from bam metally manufing inc
chromosome, start and end position of a genomic interval using the SAMtools "view" function⁶⁷. The
resulting bam files were visualise chromosome, start and end position of a genomic interval using the SAMtools "view" function". The
resulting bam files were visualised in the Integrated Genomics Viewer (IGV) (version 2.11.9) to
ascertain the nucleotides at resulting band the nucleotides at the indicated position. PGT results determined by haplarithmisis (affected, not affected, carrier, inconclusive) were compared with the putative diagnosis based on direct variant detection (affected, not affected, carrier, inconclusive) were compared with the putative diagnosis based on direct variant detection. Moreover, the expected genotype based on the haplotyping result was compared to the genotype as a (affect variant detection. Moreover, the expected genotype based on the haplotyping result was
compared to the genotype as ascertained by direct variant detection.
PGT-AO: classification of (segmental) chromosomal abnormal

compared to the genotype as ascertained by direct variant detection.
PGT-AO: classification of (segmental) chromosomal abnormalities, their segregational origin and
their level of mosaicism compared to the gener, peak as certained by an extramination in
PGT-AO: classification of (segmental) chromosomal abnormalities,
their level of mosaicism
Copy number variation (CNV) calls were visualised employing haplarit PGT-AO: classification of (segmental) chromosomal abnormalities, their segregational origin and their level of mosaicism

embryos was determined by analysing log2 ratio of the observed copy number to the expected copy
number, as indicated by logR ratios, alongside shifts in genotype frequencies of the reads, measured
by BAFs. Subsequently, th mumber, as indicated by logR ratios, alongside shifts in genotype frequencies of the reads, measured
by BAFs. Subsequently, the aberrations were classified based on several criteria. (i) the copy number
aberration detecte number, as indicated in y logit ratios, alongside shifts in genotype frequencies is the reads, instanced
by BAFs. Subsequently, the aberrations were classified based on several criteria. (i) the copy number
aberration dete by aberration detected (*i.e.* gain or loss), (ii) the size of the aberration (*i.e.* genome-wide, chromosomal,
or sub-chromosomal), (iii) the parental origin of the aberration (*i.e.* paternal or maternal), (iv) the
disc or sub-chromosomal), (iii) the parental origin of the aberration (*i.e.* paternal or maternal), (iv) the or sub-chromosomal), (iii) the parental origin of the aberration (i.e. paternal or maternal), (iv) the α

segregational origin of the aberration (in the aberration) interesting or mitosity, and (v) the degree (10%),
of mosaicism. To determine the degree of mosaicism, the genomic coordinates at the logR shift were
used to extra of mosaic mosaic mosaic mosaic mosaic surface of the location of interest. BAF values were then
compared to the reference dataset by Conlin et al. 2010⁷⁴. Besides conventional haplarithmisis that
includes a close relativ compared to the reference dataset by Conlin et al. 2010⁷⁴. Besides conventional haplarithmisis that
includes a close relative to phase the parents, "parents-only phasing" was performed by phasing the
parental genome with includes a close relative to phase the parents, "parents-only phasing" was performed by phasing the includes a close relative to phase the parents, "parents-only phasing" was performed by phasing the
parental genome with the embryo itself.
Three families with PGT-SR indications were included. Copy number variation was or

PGT for structural rearrangements

parental genome with the embry extension
PGT for structural rearrangements
Three families with PGT-SR indications w
using the Veriseq-PGS kit (Illumina Inc., S |
|
|
| Three families with PGT-Standard and Clara, CA) according to the manufacturer's instructions.
For the family that only had a PGT-SR indication, an additional TE biopsy was taken from the affected
surplus embryos to generat Examples are verited, the manufacture, same entity, any distribution of the manufacturer entity that only had a PGT-SR indication, an additional TE biopsy was taken from the affected surplus embryos to generate a WGAed DNA surplus embryos to generate a WGAed DNA sample using the REPLI-g Single Cell kit (Qiagen, Germany). In the case of families with both PGT-SR and PGT-M indications, the excess WGAed DNA was used and re-processed with our WG Surplus emaryos to generate a Western Embreshing and PGT-M indications, the excess WGAed DNA was used and re-processed with our WGS-PGT approach as described above. The data for families with dual PGT-M and PGT-SR indicati was used and re-processed with our WGS-PGT approach as described above. The data for families
with dual PGT-M and PGT-SR indications (family 1 and 9), for which close relative(s) were also
sequenced, were processed and vis with dual PGT-M and PGT-SR indications (family 1 and 9), for which close relative(s) were also
sequenced, were processed and visualised as described for PGT-M cases. Where deep sequencing
(30-40X) was undertaken, the subsa sequenced, were processed and visualised as described for PGT-M cases. Where deep sequencing
(30-40X) was undertaken, the subsampling strategy was also applied, and structural rearrangements
were assessed at all target cov (30-40X) was undertaken, the subsampling strategy was also applied, and structural rearrangements
were assessed at all target coverages. For one family (family 19) no referent individual was
sequenced, in this case each e were assessed at all target coverages. For one family (family 19) no referent individual was
sequenced, in this case each embryo was used to phase the remaining embryos. Derivative
chromosome breakpoints were ascertained sequenced, in this case each embryo was used to phase the remaining embryos. Derivative chromosome breakpoints were ascertained using Manta (v1.1.0) with default settings⁷⁵. The resulting variants were then filtered to include only break points ("BND") where pairs of "mates" were identified on the expected chromosomes. In cases where Manta did not identify identical breakpoints in the embryo, the breakpoint identified on the expected chromosomes. In cases where Manta did not identify identical breakpoints in the embryo, the breakpoints were estimated from the haplarithmisis output, specifically from the in the embryon of the phased parental BAFs and the segmentation of the logRs.
 PGT for mtDNA disorders

10 embryos from 2 families were included (Fi**g. 1b**) that were deemed affected (> transfer threshold

PGT for mtDNA disorders

segmentation of the phased parental BAFs and the segmentation of the logical PGT for mtDNA disorders
10 embryos from 2 families were included (Fig. 1b) that were deemed affecte
15%)^{39,76} for mitochondrial encephalopathy, $\frac{1}{2}$ 15%)^{39,76} for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS,
m.3243A>G) based on results from the current gold standard blastomere-biopsy (day-3) testing. The
embryos were re-biopsied on 15%)^{39,75} for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS,
m.3243A>G) based on results from the current gold standard blastomere-biopsy (day-3) testing. The
embryos were re-biopsied on d embryos were re-biopsied on day-5 to obtain a TE biopsy sample and the remaining embryo defined
as surplus embryo was also analysed to gain an accurate representation of the true heteroplasmy
level. Four TE biopsies and th embry of the the highest strate, the restaurance transportant interesting samples and the remaining the person
level. Four TE biopsies and their corresponding surplus embryos from family 20 were re-analysed
using the PCR-b as surplus embryos from family 20 were re-analysed
using the PCR-based restriction fragment length polymorphism (PCR-RFLP) protocol that was also
used to analyse the day-3 biopsy samples. The protocol was implemented as pr level. Four TE displays and their corresponding surplus embry 20 were remainly 20 were re-analyzed
using the PCR-based restriction fragment length polymorphism (PCR-RFLP) protocol that was also
used to analyse the day-3 bi used to analyse the day-3 biopsy samples. The protocol was implemented as previously described by
Sallevelt et al³⁹. Briefly, the biopsy material was subjected to cell lysis followed by two rounds of PCR. Sallevelt et al³⁹. Briefly, the biopsy material was subjected to cell lysis followed by two rounds of PCR. Sallevelt et al³⁹. Briefly, the biopsy material was subjected to cell lysis followed by two rounds of PCR.
Allevelt et al³⁹.
Intervalse of the biopsy material was subjected to cell lysis followed by two rounds of PCR.

The first amplitude is the first amplitude of the mathematic of the mathematic particle is the mutation,
after which a fluorescently labelled primer was added for the second PCR round. The resulting
product was enzymatical product was enzymatically digested, purified, and analysed by capillary electrophoresis. The mutation
load was determined by dividing the area of the mutation peak by the sum of both the wild type and
mutation peak. The re load was determined by dividing the area of the mutation peak by the sum of both the wild type and
mutation peak. The remaining four embryos from family 20 (TE biopsy and surplus embryo) were
processed with the WGS-PGT pro mutation peak. The remaining four embryos from family 20 (TE biopsy and surplus embryo) were
processed with the WGS-PGT protocol described above. These samples underwent deep sequencing
with a target sequencing depth of 30 processed with WGS-PGT and sequenced to a depth of \sim 10X. Sequencing depth per position was with a target sequencing depth of 30-40X. The sequencing data were processed and subsampled as
described above. The two embryos from family 21 (TE biopsy and surplus embryo) were also
processed with WGS-PGT and sequenced t described above. The two embryos from family 21 (TE biopsy and surplus embryo) were also
processed with WGS-PGT and sequenced to a depth of ~10X. Sequencing depth per position was
determined using the "depth" function from processed with WGS-PGT and sequenced to a depth of ~10X. Sequencing depth per position was
determined using the "depth" function from SAMtools⁶⁷. Known pathogenic variants in the
mitochondrial genome were extracted from determined using the "depth" function from SAMtools⁶⁷. Known pathogenic variants in the mitochondrial genome were extracted from the MITOMAP's confirmed pathogenic mutations database⁷⁷. The "HaplotypeCaller" function f determined using the "depth" function from SAMtools". Known pathogenic variants in the
mitochondrial genome were extracted from the MITOMAP's confirmed pathogenic mutations
database⁷⁷. The "HaplotypeCaller" function form database⁷⁷. The "HaplotypeCaller" function form GATK was used to determine the number of reads
supporting the reference and alternative alleles at the indicated position⁷⁸, from which the
heteroplasmy percentage was ca database⁷⁷. The "HaplotypeCaller" function form GATK was used to determine the number of reads
supporting the reference and alternative alleles at the indicated position⁷⁸, from which the
heteroplasmy percentage was ca supporting the reference and alternative alleles at the indicated position¹⁹, from which the heteroplasmy percentage was calculated. heteroplasmy percentage was calculated.

Data visualization
Data were visualised using R packages ggplot⁷⁹, circlize⁸⁰, ggpubr⁸¹, and cowplot⁸².

Data Availability Statement

The whole genome sequencing data cannot be shared publicly to protect the privacy of the families
that participated in the study. The anonymised data may be requested through the corresponding]
|
|}
|} The unit genome sequence is the share share in the sequence person person privacy of the families
that participated in the study. The anonymised data may be requested through the corresponding
author and via application to that participated in the study. The anonymised data may be requested intersign the corresponding
author and via application to data access committee of MUMC+. Processed data presented in this
paper, is submitted as Supplem author and via application to data access committee of MUMC+. Processed data presented in the
paper, is submitted as Supplementary Table 9.
The code of haplarithmisis and the scripts used in the analysis of this study are

Code availability

paper, in the code availability
The code of haplarithmisis and the scripts use
(https://github.com/CellularGenomicMedicine $\frac{1}{\sqrt{2}}$ The code of happens in the study are about the analysis of this study are available via Github.
(https://github.com/CellularGenomicMedicine/WGSPGT). $\frac{1}{\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac{1}{2}}\sqrt{1+\frac$

References Methods

- 39. Sallevelt, S.C., et al. Preimplantation genetic diagnosis in mitochondrial DNA disorders: challenge and
success. J Med Genet 50, 125-132 (2013).
62. Masset, H., *et al.* Multi-centre evaluation of a comprehensive preim
- success. *J Med Genet 50, 125-132 (2013).*
Masset, H., *et al.* Multi-centre evaluation
haplotyping-by-sequencing. *Hum Reprod* : 62. Masset, H., et al. Multi-centre evaluation of a comprehensive premiplantation genetic test through
haplotyping-by-sequencing. Hum Reprod 34, 1608-1619 (2019).
63. An Dijk, W., et al. Embryo tracking system for high-th
- haplotyping-by-sequencing. Hum Reprod 34, 1608-1619 (2019).
Van Dijk, W., *et al. Embryo tracking system for high-throught*
genetic testing. Hum Reprod 37, 2700-2708 (2022). 63. van Dijk, W., et *al. Embryo tracking system for high-throughput sequencing based preimplantation*
genetic testing. *Hum Reprod 37, 2700-2708 (2022)*.
64. Vasimuddin, M., Misra, S., Li, H. & Aluru, S. Efficient Archite
- genetic testing. *Hum Reprod 37, 2700-2708 (2022).*
Vasimuddin, M., Misra, S., Li, H. & Aluru, S. Efficient
Multicore Systems. *2019 IEEE International Parall*e 64. Vasimuddin, M., Misra, S., Li, H. & Aluru, S. Efficient Architecture-Aware Acceleration of BWA-MEM for
Multicore Systems. 2019 IEEE International Parallel and Distributed Processing Symposium (IPDPS),
Rio de Janeiro, B Multicore Systems. 2019 IEEE International Parallel and Distributed Processing Symposium (IPDPS),
Rio de Janeiro, Brazil, pp. 314-324 (2019).
Lawrence, M., Gentleman, R. & Carey, V. rtracklayer: an R package for interfacin
- Rio de Janeiro, Brazil, pp. 314-324 (2013).
Lawrence, M., Gentleman, R. & Carey,
browsers. Bioinformatics 25, 1841-1842 (2
- 65. browsers. *Bioinformatics* 25, 1841-1842 (2009).
66. Okonechnikov, K., Conesa, A. & García-Alcalde, F. Qualimap 2: advanced multi-sample quality control browsers. Biompormatics 25, 1841-1842 (2005).
Okonechnikov, K., Conesa, A. & García-Alcalde,
for high-throughput sequencing data. *Bioinform* for high-throughput sequencing data. *Bioinformatics* **32**, 292-294 (2016).
67. Danecek, P., *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* 10(2021).
-
- for high-throughput sequencing data. *Biomjormatics* 32, 292-294 (2016).
Danecek, P., *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* 10
Zamani Esteki, M., *et al.* Concurrent whole-genome haplotyping and co 67. Danecek, P., *et al.* Twelve years of SAMtools and BCFtools. *Gigascience* **10**(2021).
68. Zamani Esteki, M., *et al.* Concurrent whole-genome haplotyping and copy-number profiling of single
69. Van der Auwera, G.A. & 68. Zamani Esteki, M., et al. Concurrent whole-genome haplotyping and copy-number profiling of single
cells. Am J Hum Genet 96, 894-912 (2015).
69. Van der Auwera, G.A. & D., O.C.B. Genomics in the Cloud: Using Docker, GAT
- cells. Am J Hum Genet 96, 894-912 (2019).
Van der Auwera, G.A. & D., O.C.B. *Ger*
Terra (O'Reilly Media, 2020). **Ferra** (O'Reilly Media, 2020).
69. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical
- Computing, Vienna, Austria. https://www.R-project.org/ (2021). 20. R Computing, Vienna, Austria. https://www.R-project.org/. (2021).
71. Knaus, B.J. & Grünwald, N.J. vcfr: a package to manipulate and visualize variant call format data in R.
- Knaus, B.J. & Grünwald, N.J. vcfr: a package to manipulate and viennal of vienna. Austria. (2021). 21. Knaus, B.J. B. B.J. B.J. And B. Grünwald, N.J. 2017).
Mol Ecol Resour 17, 44-53 (2017).
72. Scheinin, I., et al. DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-
- Mor Ecornesour 17, 44-53 (2017).
Scheinin, I., *et al.* DNA copy numb
genome sequencing with identific Scheinin, I., *et al.* DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-
genome sequencing with identification and exclusion of problematic regions in the genome assembly.
Genome Res 24, 2022 genome sequencing contraction and exclusive representation agencies are genome assembly.
Genome Res 24, 2022-2032 (2014).
Nilsen, G., et al. Copynumber: Efficient algorithms for single- and multi-track copy number
- Genome Res 24, 2022-2032 (2014).
Nilsen, G., et al. Copynumber:
segmentation. BMC Genomics 13, 5 13. Nilsen, G., et al. Copynumber: Efficient algorithms for single- and multi-track copy number
segmentation. BMC Genomics 13, 591 (2012).
74. Conlin, L.K., et al. Mechanisms of mosaicism, chimerism and uniparental disomy
- segmentation. BMC Genomics 13, 591 (2012).
Conlin, L.K., et al. Mechanisms of mosaicism,
nucleotide polymorphism array analysis. Hum 74. Comm, L.K., et al. Mechanisms of mosaicism, chimerism and uniparental disomy identified by single
nucleotide polymorphism array analysis. Hum Mol Genet 19, 1263-1275 (2010).
75. Chen, X., *et al.* Manta: rapid detectio
- nucleotide polymorphism array analysis. *Hum Mol* Genet 19, 1263-1275 (2010).
Chen, X., *et al.* Manta: rapid detection of structural variants and indels for
sequencing applications. *Bioinformatics* 32, 1220-1222 (2016). For Chen, X., et al. Manta: rapid detection of structural variants and indels for germine and cancer
sequencing applications. *Bioinformatics* 32, 1220-1222 (2016).
76. Chinnery, P.F., Howell, N., Lightowlers, R.N. & Turnb
- sequencing applications. Biompormatics 32, 1220-1222 (2016).
Chinnery, P.F., Howell, N., Lightowlers, R.N. & Turnbull, D.N.
MERRF. The relationship between mutation load and clinical 76. Chinnery, P.F., Howell, N., Lightowlers, R.N. & Turnbull, D.M. Molecular pathology of MELAS and
MERRF. The relationship between mutation load and clinical phenotypes. *Brain* **120 (Pt 10)**, 1713-
1721 (1997). Lott, M.T MERRF. The relationship between mutation load and clinical phenotypes. *Brain* 120 (Pt 10), 1713-
1721 (1997).
Lott, M.T., *et al.* mtDNA Variation and Analysis Using Mitomap and Mitomaster. *Curr Protoc*
- ، ُLott, M.T
B*ioinformatic* Fort, M.T., et al. merical variation and Analysis Using Mitomap and Mitomaster. Carr Protoc
Bioinformatics 44, 1.23.21-26 (2013).
78. McKenna, A., et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing nex
- Biompormatics **44**, 1.23.21-26 (2013).
McKenna, A., *et al.* The Genome *I*
generation DNA sequencing data. Ger 78. McKenna, A., *et al.* The Genome Analysis Toolkit: a MapReduce framework for analy
generation DNA sequencing data. *Genome Res* 20, 1297-1303 (2010).
79. Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*, (Spri
-
- generation DNA sequencing data. Genome Res 20, 1297-1303 (2010).
Wickham, H. *ggplot2: Elegant Graphics for Data Analysis*, (Springer-Ve
Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements ar 79. Wickham, H. ggplot2: Elegant Graphics for Data Analysis, (Springer-Verlag New York, 2016).
80. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize Implements and enhances circular vi
in R. Bioinformatics 30, 2
- 81. Guinformatics **30**, 2811-2812 (2014).
81. A., K. ggpubr: 'ggplot2' Based Publication Ready Plots, (2023).
82. Wilke, C.O. cowplot: Streamlined Plot Theme and Plot Annotat in R. Biomjormatics **30**, 2811-2812 (2014).
A., K. ggpubr: 'ggplot2' Based Publication F
Wilke, C.O. cowplot: Streamlined Plot Then
- 82. A., K. ggpubr: ggplot2 Based Publication Ready Plots, (2023).
82. Wilke, C.O. cowplot: Streamlined Plot Theme and Plot Annotations for 'ggplot2', (2020).

logR \circ $\,0\,$ -1 -1 1.0 1.0 Pat-BAF-emb 0.5 0.5 補請 0.35 0.0 0.0 1.0 1.0 Mat-BAF-emb

 $logR$

Pat-BAF-emb

Mat-BAF-emb

 0.5

 0.0

parents-only phasing

0.66

 0.5 0.0

0.34

0.65

0.66

Family 1: paternal t(8;16)

- Manta breakpoints

